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The TCA cycle is the midpoint of a cell’s metabolism. It’s amphibolic character allows 
on one side the production of ATP, on the other side provides precursors for many 
biosynthetic pathways. Although hexoses are the preferred carbon source for most 
organisms, many bacteria such as Escherichia coli and Mycobacterium tuberculosis, are 
also able to grow on fatty acids or acetate as sole source of carbon and energy. This 
though, requires the operation of the anaplerotic sequence of the glyoxylate shunt. Under 
these circumstances, the glyoxylate bypass enzyme isocitrate lyase (ICL) is in direct 
competition with the TCA’s cycle enzyme isocitrate dehydrogenase (ICD) for their 
common substrate isocitrate. As was found in E. coli, control of the glyoxylate bypass 
implies the increased expression of ICL, which is accompanied by modulation of ICD 
activity through a reversible phosphorylation by a isocitrate dehydrogenase 
kinase/phosphatase (ICDK/P).  
 
The branch point in M. tuberculosis is more complex compared to E. coli. There are two 
icl genes (icl-1 and icl-2) and two icd genes (icd-1 and icd-2). The genes are 
phylogenetically not related. How M. tuberculosis regulates the glyoxylate shunt/TCA 
cycle branch point is currently unknown. However, bioinformatics predicted that the 
branch point has to be regulated by phosphorylation of ICD-1. 
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The understanding of the regulation of this branch point is of major importance, since it’s 
believed that fatty acids are the main source of carbon and energy for M. tuberculosis in 
chronically infected animals and in man. 
 
In this project, we aimed at finding this particular kinase/phosphatase in Mycobacterium 
bovis BCG. Further, we wanted to gain some insight into the coordinate regulation of this 
branch point. In order to pursue  these purposes, we implemented to extract the putative 
kinase/phosphatase using an affinity column containing resins that bind ATP-binding 
proteins. In context with that, we also purified the substrates of the putative 
kinase/phosphatase, the two M. tuberculosis isocitrate dehydrogenases, ICD-1 and ICD-
2, and tested their enzymatic activity. 
 
From studies in E. coli it is known that the involvement of the glyoxylate bypass in 
metabolism depends on the nature of the available carbon source(s) and further, that the 
direction of the carbon flux into this bypass is dependent on the phosphorylation status of 
isocitrate dehydrogenase. Based on this, we tried to examine the phosphoproteom of 
BCG when either grown on glucose or on acetate by using a column, whose beads had an 
affinity for phosphoproteins. Since it was known that in E. coli the 
phosphorylation/dephosphorylation of ICD was carried out at the amino acid residue 
serine 113, we used Ser/Thr antibodies in order to detect the Ser/Thr phosphoproteins, 
among which we would eventually find ICD-1 and/or ICD-2. In addition, we created a 
BCG mutant strain expressing a modified E. coli ICD enzyme, dubbed ICDopt, which did 
not permit phosphorylation at its serine 113. With this construct we aimed in 
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dysregulating the branch point in BCG. This would possibly allow to proof the concept 
that the branch point in M. tuberculosis is regulated analogue to the one in E. coli. 
 
 
During the course of this project, we were neither able to extract the putative ICDK/P in 
BCG, nor gaining insight into the phosphoproteom and its dependence on the carbon 
source. Moreover, when growing BCG expressing ICDBoptB in either glucose or acetate 
based medium, we found no major phenotypic alterations in comparison to wt BCG. In 
order to pursue the intention of dysregulating the branch point we constructed a BCG 
∆icd-1 and a BCG ∆icd-2 knockout mutant. Performing growth assays with these two 
constructs showed no phenotypic differences when compared to wt BCG. Furthermore, 
measuring ICD enzyme activity we found no major differences between BCG ∆icd-1 and 
wt BCG. However, no isocitrate dehydrogenase activity was detected in the BCG ∆icd-2 
strain. This result was surprising since 1) it suggested that ICD-1 does not contribute to 
the overall isocitrate dehydrogenase activity in BCG and 2) the growth kinetic of the 
BCG ∆icd-2 strain was comparable to the growth of the parental strain on all tested 
carbon sources. We demonstrated that the BCG ∆icd-2 knockout mutant achieved 
optimal growth by diverting the carbon flux through the glyoxylate shunt, even on 
glucose or glycerol. These results were confirmed by showing that the BCG ∆icd-2 strain 
is deficient for the synthesis of α-ketoglutarate (the end-product of the reaction catalyzed 
by ICD), thereby rendering the mutant strain auxotrophic for glutamic acid. 
Overall, these results suggest that ICD-2 is the only ICD enzyme active in BCG. The 
reasons why ICD-1 is not enzymatically active are not clear, but it could be explained by 
a lack of expression or by a constitutive phosphorylation of the enzyme at the active site. 
Indeed, much more work needs to be done for the better understanding of the regulation 
of this branch point. Based on our experimental findings, we predict that ICD-1 and ICD-
2 differ in their function and possibly in their form of regulation by the putative isocitrate 
dehydrogenase kinase/phosphatase. 
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1.1 Tuberculosis from a Global Perspective  
1.1.1 Burden of Tuberculosis 
Tuberculosis (TB) belongs with approximately 3 million annual deaths worldwide to the 
group of “big killer diseases”. In 2006 there were according to WHO an estimated 9.2 
million new cases of TB (139 per 100,000 population; Figure 1), including 0.7 million 
HIV-positive cases (8% of the total).  
 
Figure 1.1 | Global Burden. Estimated TB incidence rates by country, 2006.  
(WHO/HTM/TB/2008.393) 
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Further, there were an estimated 14.4 million prevalent cases and an estimated 1.7 million 
deaths, out of which 0.2 million were HIV positive. Approximately 1.5 million cases 
were said to have multidrug-resistant tuberculosis (MDR-TB). The incidence of 9.1 
million cases in 2005 increased to 9.2 million cases in 2006, which is most probably due 
to population growth. South-East Asia along with the Western Pacific regions account for 
55% of global cases, and Africa accounts for 31%. Comparing the absolute number of 
cases; India, China, Indonesia, South Africa and Nigeria rank first to fifth respectively. 
Africa has the highest incidence rate per capita (363 per 100,000 population), as well as 
the highest incidence of HIV-related TB since TB control in Africa is dominated by the 
worsening HIV epidemic. 
 
These numbers demonstrate that TB control is difficult and even though it is a curable 
disease, many people still die from it. In response to this situation, a global control 
strategy, called DOTS (Directly Observed Therapy, Short-course), was introduced by 
WHO. The basic five components of the DOTS strategy are: 
 
1 Sustained political commitment with increased and sustained financing. 
2 Case detection through quality-assured bacteriology, i.e. guarantee access to quality 
assured sputum microscopy. 
3 Standardised short-course chemotherapy for all cases of TB under proper case 
management conditions, including direct observation of treatment. 
4 Uninterrupted supply of quality-assured drugs in context with an effective 
management system. 
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5 Recording and reporting system, enabling outcome assessment of all patients and 
assessment of overall programme performance. 
 
The DOTS approach is nowadays one of the most important “Stop TB” Strategies. WHO 
reported that in 2006, out of the estimated 9.2 million new cases, 54% were detected by 
DOTS program.  
(WHO/CDS/TB/2003.313), (WHO/HTM/TB/2008.393), (www.who.int/tb/en/) 
1.1.2 Global Epidemiology  
The distribution of tuberculosis within different populations and/or regions depends on 
the transmission. The incidence rate was shown to be highest among young adults, where 
transmission has been stable or has increased over decades and most cases were 
attributable to a new infection or reinfection. In comparison, the caseload changes in 
older adults, where transmission is falling and most cases are due to reactivation of latent 
infection. In countries with low incidence rates such as Western Europe and North 
America, native tuberculosis patients are usually old, while immigrants from countries 
with high-incidence tend to be younger (Dye, 2006).  
The comparatively few cases that are found among children (i.e. between 0-14 years old), 
even in countries with high transmission, may not reflect the reality due to the fact that 
diagnosis of childhood tuberculosis is difficult.  
Also, there is a higher number of smear-positive cases found in men than in women (1.4 
million compared to 775,000 in 2004). One explanation is that women have poorer access 
to health facilities, but it is also an indication of the real epidemiological differences in 
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exposure to infection and susceptibility to development of active disease between the 
genders (Dye, 2006). 
The global increase in tuberculosis incidence is ascribable to the remarkable increase of 
cases in countries of Eastern Europe (principally the former Soviet Union) since 1990, 
and in sub-Saharan Africa since the mid-1980. The reason for the resurgence of 
tuberculosis in Eastern Europe can be explained by the worsening of the economical 
situation such as increased levels of unemployment, by the deteriorating public health 
systems and the general failure of tuberculosis control (Frieden et al., 2003), (Olusoji 
Adeyi et al. 2007). Interesting to mention is that from a global point of view, only 3% of 
all new tuberculosis cases are said to be multidrug resistant. However, the frequency is 
higher in so-called hotspot areas, e.g. parts of Eastern Europe. TB patients in Eastern 
Europe and central Asia are ten times more likely to have MDR-TB than in other parts of 
the world, and 5.5% of the new cases are MDR-TB (Olusoji Adeyi et al. 2007). Overall it 
seems that currently, in Eastern Europe as well as in sub-Saharan Africa, the rate of 
increase has slowed since the mid-1990s and in Eastern Europe it might even be in 
decline (Dye et al., 2005).  
From 2004 onwards, the worldwide continued increase is estimated to be wholly 
attributable to the increase of cases in Africa, and HIV plays an important role. 
Worldwide, in 2004, around 13% of the new tuberculosis cases in adults were HIV 
infected. Regional differences where immense, with 34% in Africa but only 1.4% in the 
Western Pacific region. Further, it was shown that areas in Africa, where HIV infection 
rates were high in the general population, also had a high number of patients with 
tuberculosis and a high proportion of those tuberculosis patients were women between 
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15-24 years old. In 2004, co-infection with tuberculosis exceeded 50% in countries like 
Botswana, South Africa, Zambia and Zimbabwe (WHO/HTM/TB/2006.362). Overall, the 
increase in tuberculosis cases in Africa is slowing, most probably because HIV infection 
rates are stabilizing or even falling (Dye, 2006). It is also believed that HIV has a smaller 
impact on tuberculosis prevalence than on incidence, since life expectancy of tuberculosis 
patients is significantly diminished when infected with HIV (Corbett et al., 2004). 
Unfortunately, because HIV has had and presently still does have a big influence on 
tuberculosis epidemiology, other important risk factors such as chronic diseases 
(diabetes, undernutrition, respiratory illnesses due to tobacco and air pollution) have been 
somewhat neglected (Dye, 2006).  
Tuberculosis kills young adults and over 80% of DALYs (disability-adjusted life years) 
are lost because of premature death rather than illness. Global and regional trends in 
tuberculosis deaths are vague, because most countries with high tuberculosis burden do 
not compile reliable statistics on the cause of death. Nevertheless, it has been indicated 
that death rates from tuberculosis, after having risen during the 1990s, might have been 
falling since 2000 (Dye, 2006). 
In 1991, the WHO was aiming to detect 70% of all infectious cases of tuberculosis and to 
cure 85% of them by 2005. Unfortunately, the reality nowadays shows that although 
more than 80% of known cases are successfully treated, only 45% of the cases are 
detected. New targets were set by Millennium Development Goals and Stop TB 
Partnership, but in order to meet them, the generation and implementation of new 
information is needed (Onyebujoh et al., 2006). 
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1.2 History of Tuberculosis 
1.2.1 The Origin 
The M. tuberculosis complex (MTBC) includes the human and animal pathogens M. 
africanum, M. microti, M. canetti, M. tuberculosis and M. bovis. It has emerged probably 
some 40,000 years ago from its progenitor in East Africa, the region, where at the same 
time the dissemination of modern human populations started. The two main lineages of 
MTBC arose later, some 20,000 to 30,000 yeas ago. One of the two lineages spread 
exclusively among humans, whereas the other is believed to have spread from humans to 
animals. The latter one includes the pathogens M. bovis and M. caprae. The transition 
from human to animal hosts can be related to the plant and animal domestication that 
took place some 13,000 years ago in the fertile Crescent (Wirth et al., 2008).  
The use of comparative genomics and related technologies allowed discrimination 
between the members of the MTBC by comparison of the distribution of RDs (deleted 
regions within the genome). It was found that M. tuberculosis strains are more closely 
related to the common ancestor of the MTBC than are M. bovis strains. It seems plausible 
that a separate lineage, represented by M. africanum, M. microti and M. bovis, evolved 
from the progenitor of nowadays’ M. tuberculosis isolates and adapted to new hosts. 
Whether the progenitor of M. tuberculosis was already a human pathogen or not, remains 
to be determined (Brosch et al., 2001).  
It is of importance to note that archeological evidence of early tuberculosis is not only 
found in East Africa but also in America. It is believed that the disease occurred 
throughout America, prior to the arrival of the first European explorers (Daniel, 2006). 
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1.2.2 The Great White Plague 
The epidemic spread of TB was slow but urbanisation in feudal Europe, which resulted in 
increased population density and thus, allowed person-to-person spread of the tubercle 
bacilli, set off an epidemic that came to be called “The Great White Plague”. From the 
17th to the 18th century, almost all Western Europeans were infected and one in four 
deaths were due to tuberculosis. As infected Western Europeans started travelling to 
colonize alien lands and migrants later started to settle down, almost of all in North 
America, the epidemic followed them and finally, the disease spread worldwide. In the 
18th and 19th century, tuberculosis peaked in West Europe and the United States and was 
the largest cause of death. 100-200 years later, it had disseminated to Eastern Europe, 
Asia, Africa and South America. (Daniel, 1994) 
1.2.3 Aetiology of Tuberculosis  
Tuberculosis was well-known in ancient Greece. Hippocrates recognised tuberculosis and 
understood the clinical manifestation of the disease. Nonetheless, nothing significant 
happened in the history of tuberculosis until the 9th and 10th centuries. It was around 
1020, when Ibn Sina, a Persian physician and philosopher, also known by his latin name 
Avicenna, suggested the communicable nature of the disease. He wrote excellent 
descriptions of the clinical features and the pathology of tuberculosis and developed a 
method of quarantine (Daniel, 1994). Much later, in 1689, Dr. Richard Morton 
established that the pulmonary form of the disease was associated with “tubercles”. As 
late as in the 1820s, tuberculosis was identified as a single disease and in 1839 was 
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termed “tuberculosis” by J.L.Schönlein. Also during that time, tuberculosis sanatoria 
were established (Figure 1.2) and became common throughout Europe from the end of 
the late 19th century onwards (Daniel, 1994). It was Robert 
Koch in 1882, who changed the thinking about tuberculosis. He 
described the tubercle bacillus M. tuberculosis and 
demonstrated it to be the cause of tuberculosis using his famous 
postulates, the Henle-Koch postulates. To this day, they are the 
standard for the demonstration of infectious etiology (Daniel, 
2006). Further, he isolated a substance from tubercle bacilli that 
he called tuberculin. With this and other achievements such as 
development of staining techniques and implementation of 
cultures on solid media, Robert Koch can be thought as the 
founder of the science of microbiology (Daniel, 2006). Overall, 
it was the first time that a disease was directly correlated to bacteria. In 1906 Albert 
Calmette and Camille Guérin developed a vaccine for immunising against tuberculosis, 
termed BCG (Bacillus of Calmette and Guérin) vaccine, which derived from the 
attenuated strain of M. bovis. It was first used in humans in 1921 in France, but received 
worldwide acceptance only after World War II (Daniel, 1994). 
Figure 1.2 | The search 
for a cure. At the end of 
the 19th century, 
sanatoria such as 
Valmora were 
established as a solution 





The grim and often infaust prognosis of tuberculosis changed dramatically in November 
1944, when a woman, who failed to respond to the common anti-tubercular treatment at 
that time – rest and thoracoplasty – was treated with streptomycin, isolated only 11 
months earlier by Selman Waksman, got cured. Similar were the first results with patients 
treated with isoniazid. With these striking results, the era of successful chemotherapy for 
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tuberculosis seemed to be launched, and people thought that the conquest of tuberculosis 
was within one’s reach (Daniel, 1994).  
1.3 Transmission and Progression 
Worldwide, every third person is said to be latently infected with M. tuberculosis. 
Individuals with prolonged, frequent or intense contact have a particularly high chance of 
becoming infected; the estimated infection rate lies around 22%. A person with untreated, 
active tuberculosis can infect 10-15 other individuals per year. Further at risk are people, 
who live in areas where tuberculosis is a common disease; low-income and/or medically 
neglected populations; people with poor nutrition; people living in crowded or unsanitary 
living condition; elderly people and infants, especially when exposed to adults in high-
risk categories; immunocompromised people, especially HIV/AIDS patients, persons, 
whose immunity is suppressed, especially those on long term steroids; diabetics; health 
care workers; and drug abusers.  
Even though the great majority of infected individuals are latent, asymptomatic carriers 
of M. tuberculosis and do not exhibit any clinical symptoms, they represent slow-release 
reservoirs. Latently infected individuals have a 2-23% lifetime risk of developing 
reactivation of the disease and this risk increases to 10% per annum in persons with 
immunodeficiency states, mostly due to HIV co-infection.  
Disease reactivation and the subsequent primary infection of immunocompromised 
individuals results in more than 3 million deaths annually. (www.infektionsbiologie.ch), 
(WHO/CDS/TB/2003.313), (www.who.int/tb/en/) 
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The spread of the disease (Figure 1.3) can occur only from people with active, but not 
latent tuberculosis. Individuals become infected by the inhalation of air-borne droplet 
nuclei containing M. tuberculosis. Transmission is dependent on the number of infectious 
droplets expelled by the carrier, the duration of exposure and the virulence of the M. 
tuberculosis strain. Since tuberculosis is spread from person to person, isolation of 
patients with active disease is an efficient strategy to break the chain of transmission. 
Subsequent anti-tubercular drug treatment of patients with active but non-resistant 
tuberculosis, generally results in cessation of transmission after two weeks (Zahrt, 2003).  
 
 
Figure 1.3 | Transmission and progression with M. tuberculosis. Tuberculosis is spread by aerosols and 
can lead to an infection, which results in the formation of a primary lesion. Around 3 weeks upon first 
infection of unimmunised humans, the bacilli spread haematogenously. In 90-95% the infection remains 
latent. 5-10% of infected individuals show a progression of the disease. Mostly, the disease remains latent 
for decades, but can be reactivated due to suppression of the immune system (e.g. HIV). Progression of 
the disease leads to cavity formation and hence, to active TB, which results in the spread of the bacilli by 
aerosols {Rook, 2005 #61}. 
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1.4 Clinical Manifestations 
The disease affects primarily the lungs in “discrete consolidated foci”, named 
granulomas. Tuberculosis can be divided into active disease, characterised by the 
microscopic detection of viable bacteria in a patients sputum; and latent disease, where 
no overt signs of disease symptoms are exhibited. In the latter case, only a delayed-type 
hypersensitivity reaction, provoked by challenging a patient with purified protein 
derivative (PPD) subcutaneously, can provide evidence of being infected with M. 
tuberculosis (Boshoff and Barry, 2005). In 75% of cases with active disease the lungs are 
affected (pulmonary tuberculosis). The typical symptoms include chronic cough with 
blood-tinged sputum, chest pain, fever, night sweats, weakness and weight loss. The 
other 25% of active cases develop extrapulmonary tuberculosis, also termed disseminated 
tuberculosis or milliary tuberculosis. It spreads via the blood system and can attack the 
central nervous system (meningitis), the circulatory system, the lymphatic system 
(scrofula), the gastrointestinal system, the genitourinary system, bones (Pott’s disease), 
joints and the skin (lupus vulgaris); (Frieden et al., 2003), (Smith, 2003). Infection at 
these sites provokes a variety of different symptoms. It appears as complication in 1-3% 
of all tuberculosis cases and occurs more frequently in people with weakened immune 
system, in people that had known tuberculosis with inadequate treatment, and infants. 
Although not contagious, it may co-exist with pulmonary tuberculosis, which in turn is 
infectious (Smith, 2003). 
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1.5 Pathogenesis  
Infection of M. tuberculosis occurs via inhalation of the bacillus into a pulmonary 
alveolus. The first contact is thought to be with resident, alveolar macrophages and with 
dendritic cells. Dendritic cells play a very important role in this early stage of infection, 
since they are much better antigen presenting cells than are macrophages. They are also 
said to be essential in terms of T cell activation and dissemination of the bacilli due to 
their migratory feature (Smith, 2003). 
M. tuberculosis is phagocytosed upon binding to a macrophage mannose and/or 
complement receptor. Within the host macrophage, the bacterium initially resides within 
an endocytic vacuole. The normal progression of the phagosome is characterised by 
phagosome-lysosome fusion, along with various alterations in the environment. The 
milieu becomes very hostile and the bacilli encounter acidic pH, reactive oxygen 
intermediates (ROI), lysosomal enzymes, toxic peptides and reactive nitrogen 
intermediates (RNI). RNIs were shown to be very effective against virulent mycobacteria 
in mouse macrophages and it was observed that resistance to RNIs correlates with 
virulence of M. tuberculosis (Smith, 2003).  
Although macrophages in general provide an effective initial barrier against pathogens, 
M. tuberculosis has evolved many evasion strategies that allow survival within the 
phagocytic cell. One evasion mechanism is the inhibition of phagosome-lysosome fusion, 
thereby preventing M. tuberculosis from degradation. It has been observed that 
phagosomes containing pathogenic mycobacteria differ from the ones harbouring non-
pathogenic strains (Koul et al., 2004). For example are many characteristics of early 
    31  
    32  
endosomes retained in phagosomes harbouring pathogenic bacilli. The pH fails to acidify 
below pH 6.2 and the endosomal compartment remains positive for a range of early 
endosomal markers. One of them is rab5, a member of the small GTPases. It was found 
that the persistence of rab5 and the absence of rab7, a marker of the late endosome, is 
consistent with the arrest of the maturation from early to late endosome (Pethe et al., 
2004), (Pieters, 2001). Another protein, termed TACO, was found to be associated with 
infected cells and is actively retained at the mycobacterial phagosome membrane and 
thus, prevents phagosome-lysosome fusion. Interesting to mention is the finding that the 
Kupffer cells in the liver, which is the major clearance site for mycobacterial infections, 
lack TACO (Pieters, 2001). Overall, how the tubercle bacilli achieve the arrest of 
phagosomal maturation is currently not known. Data from different groups suggest that 
more than one mechanism may be responsible for the process of arrest (Pethe et al., 
2004). 
Other evasion strategies include the inhibition of apoptosis and stimulation of bactericidal 
responses by interfering with signalling pathways that involve MAPKs, IFN-γ and 
calcium signalling (Koul et al., 2004). Antigen presentation seems also to be altered due 
to interactions of bacterial components with TLR2, which results in a decreased 
expression of MHC class II molecules. On the other hand, the production of inhibitory 
cytokines like IL-10 and TGF-β is increased (Smith, 2003). 
Alveolar macrophages, which are not able to eliminate the ingested bacilli, eventually 
burst, because of continuous multiplication of the pathogen. This results in the release of 
the bacilli into the surrounding environment and to further ingestion by other alveolar 
macrophages and by inactivated monocytes, lymphocytes and neutrophils recruited from 
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the peripheral blood. Unfortunately, none of these immune cells kill the bacteria very 
efficiently (Dannenberg, 1994). At that stage, a primary lesion (Figure 1.4), usually in the 
mid-region of the lung, composed of macrophage-derived giant cells and lymphocytes, 
begins to form. This lesion along with the draining and affected lymph nodes is referred 
to as the Ghon Complex and is thought to enable the spread of bacteria through the 
draining lymphatic system into the bloodstream. This in turn leads to reinfection of apical 
pulmonary regions and to the formation of secondary lesions, small tubercles with 





The onset of a cell mediated immune response, which is characterised by the migration of 
T lymphocytes to the site of infection, kills the infected macrophages. However, it also 
results in tissue-damaging due to the release of lysozyme and TNF-α from activated 
macrophages. As a consequence, caseous necrosis develops within the centre of the 
Figure 1.4 | Composition of granulomas. The granuloma is the site of infection, persistence and 
pathology. It is also the site of protection {Kaufmann, 2001 #65}. The centre of a granulomas is 
composed mainly of necrotic tissue, multinucleated giant cells (fused macrophages) and epitheloid-like 
cells. The periphery consists of activated macrophages and T lymphocytes {Zahrt, 2003 #10}. 
lesion. Bacilli are able to survive in the caseum but cannot multiply, because of the 
hostile environment (anoxic conditions, acidic pH, toxic fatty acids). In this foci the 
bacteria are able to persist for decades (Smith, 2003). Along with the events stated above, 
the host becomes tuberculin positive, due to the tuberculin-like products of the bacilli. It 
is to remark that the local tissue damage is necessary in order to control bacillary 
multiplication. After such control is established, activated macrophages can accumulate 
around the caseous and prevent the extension of the disease.  
A cell mediated immune response produces antigen specific T cells, which attract 
monocytes from the bloodstream and activate them. This is important since only 
activated macrophages are capable of degrading the bacilli. Macrophage activation 
occurs also upon interaction with lymphokines, endotoxin-like bacillary products and 
ingestion of dead cells and tissue debris (Dannenberg, 1994).  
Importantly, it is the strength of the adaptive immune response that determines the fate of 
the infection. In individuals with effective cell mediated immunity, the infection may be 
arrested permanently at this point. The granulomas heal and only small fibrous and 
calcified lesions are left. Although the infection is arrested, it is believed that the bacilli 
are not eliminated but persist throughout a person’s lifetime in an asymptomatic and non-
transmissible state. This enclosed infection is referred to as latent or persistent 
tuberculosis (Smith, 2003). In contrast, individuals that fail to control the initial infection 
in the lung or alternatively, experience reactivation of the tubercle bacillus from latency, 
develop active disease. Thereby, granuloma centres enlarge and the bacilli may spread 
hematogenously. Further, they develop multiple uncontrolled tubercles with caseation in 
not only the lungs, but also in extrapulmonary sites (Dannenberg, 1994). The progression 
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of primary tuberculosis, an unknown process till date, leads to the liquefaction of the 
caseous lesions. The liquefied material serves as growth medium for the bacilli and this 
allows them to multiply extracellular, which they do often in great quantity and thus 




Figure 1.5 | Main characteristics of tuberculosis. In this picture the three potential outcomes of a TB 
infection are depicted. a | The spontaneous healing of a TB infection is not known but is assumed to be 
minute. b | Development of disease can occur directly after infection in immunocompromised hosts.  
c | In the majority of cases, disease develops much later after infection as a result of reactivation. The 
key players of the adaptive immune response are the different effector T cell populations and the 
macrophages. Macrophages are activated by IFN-γ and TNF-α, which are both released by T cells. 
Activation leads to phagosome-lysosome fusion and to the production of antibacterial molecules such  
as RNI and ROI {Kaufmann, 2001 #65}. 
Macrophages don’t survive in liquefied (or even solid) caseous material. Hence, activated 
macrophages are ineffective in controlling the extracellular multiplication of tubercle 
bacilli. Host sensitivity towards tuberculin-like products of the bacillus has a toxic effect 
to the tissue, resulting in necrosis and rupture of nearby bronchi. This finally results in 
the formation of a cavity (Dannenberg, 1994).  
A cavity consists of an external zone that encapsulates the cavity and a liquefying internal 
zone, where the high oxygen content from the ambient air allows bacterial growth. Via 
this cavity, bacilli and the liquefied caseous material can be discharged, e.g. by coughing, 
into the airways and thus, reach other parts of the lungs and the external environment. 
The infected host becomes a source of infection and can spread tubercle bacilli to other 
persons. As for a caseous focus, a “healed” cavity is rarely completely free of bacteria, 
meaning that bacteria may also persist in this ambit for many years (Dannenberg, 1994), 
(Smith, 2003). The main characteristics of tuberculosis are depicted in Figure 1.5.  
1.6 Diagnostics 
Tuberculosis can be diagnosed using different methods, as for instance X-ray, staining of 
sputum smear and immunoassay tests. An abnormal chest X-ray can provide an 
indication of tuberculosis. However, chest X-ray findings often resemble findings from 
other diseases.  
The gold standard though is still the direct demonstration of the tubercle bacilli from a 
patients sputum in Löwenstein-Jensen culture medium. Unfortunately, this method 
requires usually 3 to 8 weeks due to the slow growing nature of M. tuberculosis. 
    36  
    37  
Microscopic examination is much faster but also less accurate. Staining methods include 
fluorochrome staining, Ziehl-Neelesen staining with carbon-fuchsin, also referred to as 
acid-fast staining, and Kinyoun staining method. Sputum does generally provide an 
adequate sample from the lung. Occasionally, bronchoscopy is necessary in order to 
obtain samples of mucus or lung tissue and to examine the bronchial tubes. Smear 
staining followed by microscopy is time consuming due to the slow growth of the 
bacteria. PCR technologies nowadays allow identification of pathogenic DNA within a 
day. (Andersen et al., 2000), (www.infektionsbiologie.ch) 
The tuberculin skin test, also known as Mantoux test, uses PPD to provoke a so-called 
delayed hypersensitivity response. It displays a T cell activation. Although an important 
tool to diagnose tuberculosis, it only indicates that a bacterial infection has taken place 
some time in the past. It does not reveal if the infection is currently active. More over, 
this test has poor specificity and shows cross-reactivity with BCG vaccination. At 
present, the tuberculin skin test is used to diagnose latent infection in non-immunised 
individuals. (Andersen et al., 2000), (Frieden et al., 2003) 
 
The Quantiferon test is a new in vitro diagnostic test that measures the release of IFN-γ 
from peripheral blood T lymphocytes, following stimulation with a specific M. 
tuberculosis antigen (ESAT-6). This test has good sensitivity and specificity and is also 
applicable after a BCG vaccination. However, this test is very expensive and hence, is of 
limited use in developing countries. Further, it is still unknown how well this test can 
measure the risk of reactivation of a latent infection (Andersen et al., 2000). 
1.7 Prevention 
One main aspect of controlling tuberculosis is: stopping the spread of the disease by early 
case searching and treatment of an early infection before development of active disease. 
Further, monitored treatment (DOTS) of active tuberculosis cases over 6 months is 
unremitting. Other essential control strategies include socio-economic improvements in 
living standards and exposure prophylaxis, e.g. for relatives of a tuberculosis case.  
(www.infektionsbiologie.ch), (WHO/HTM/TB/2008.393) 
The BCG vaccine is still much in use in developing countries, especially to prevent 
development of the deadly form of the disease in children (meningitis and miliary 
tuberculosis). It is very safe and cheap and offers a good protection to children in terms 
of dissemination, but is of limited use in adults due to inefficient protection. Even though 
new vaccines have been developed, none of them have shown to be significantly better 
than the BCG vaccine (Frieden et al., 2003).  
Since tubercle bacilli are spread from person to person, early recognition and subsequent 
treatment (including isolation) of active disease is very important. 
1.8 Treatment 
Treatment of Tuberculosis has several aims, which are to cure a patient from 
tuberculosis, to prevent death from active disease or from its late effects, to prevent 
relapse, to reduce transmission and to prevent the development of acquired drug 
resistance (WHO/CDS/TB/2003.313). 
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1.8.1 First-Line Antituberculosis Drugs 
The first line antituberculosis drugs are isoniazid, rifampicin, pyrazinamide, streptomycin 
and ethambutol. These drugs are the most efficient bactericidal drugs and active against 
all populations of tuberculosis bacilli. Their main properties are their bactericidal and 
sterilizing activity and the prevention of resistance (WHO/CDS/TB/2003.313).  
 
Isoniazid (INH) is a prodrug and is activated by KatG, a catalase-peroxidase 
hemoprotein. INH inhibits InhA, a NADH-specific enoyl-acyl carrier protein reductase. 
This process inhibits the synthesis of mycolic acids required for the mycobacterial cell 
wall. In humans, INH shows a high early bactericidal activity that kills actively growing 
bacteria. For the first two weeks of treatment, INH causes rapid decrease in sputum 
bacilli. Afterwards, the decrease slows down for non-growing bacterial populations. 
Concerning adverse effects in humans, it is to mention that INH crosses the placental 
barrier. This requires strict observations of the neonate of an INH-treated mother for any 
anomalous effects (Brennan et al., 2008).  
 
Rifampicin (RIF) inhibits the activity of the β-subunit of DNA-dependent RNA 
polymerase, which acts early in transcription. By binding the β-subunit in close proximity 
to the RNA/DNA channel, the transit of the growing RNA chain is physically blocked. 
RIF is the most efficient drug in terms of sterilising activity since it is very effective 
against persistent bacilli in the continuation phase of treatment. Potential toxic effects in 
humans include hepatotoxicity, though is generally rare with RIF alone. However, pre-
existing conditions can have an intensifying effect. For RIF (10 mg/kg) it was reported 
that clinically apparent liver toxicity occurred in 2-5% of cases and altered liver function 
tests in 10-15% of cases (Brennan et al., 2008).  
 
Pyrazinamide (PZA) and streptomycin (STR) are also bactericidal, but only against 
certain bacteria populations or rather, pyrazinamide is only active in an acidic 
environment and streptomycin is active against fast multiplying tubercle bacilli. The 
mechanism of action of PZA is poorly understood. It was found that it inhibits different 
functions at acid pH. PZA is essential in the treatment of tuberculosis meningitis since it 
crosses inflamed meninges. Concerning adverse effects in humans, PZA should not be 
used for treatment of latent tuberculosis, because the rate of hepatotoxicity is 
unacceptably high.  The mode of action for streptomycin (STR) is the inhibition of 
protein synthesis by binding to the conserved A site of the 16S rRNA in the 30S 
ribosomal subunit. STR shows rapid development of resistance in humans and has the 
potential to cause serious neurotoxic effects in humans (Brennan et al., 2008).  
 
Ethambutol (ETH) inhibits cell-wall biosynthesis by inhibiting arabinosyl transferases. 
This drug is effective against actively growing mycobacteria, including M. tuberculosis. 
It is used in combination with other first-line drugs in order to avoid the emergence of 
genetic resistance to the drugs. The most severe toxic effects of the drug found in humans 
include optic neuropathy and occasional hepatotoxicity (Brennan et al., 2008). 
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1.8.2 Regimen 
Tuberculosis treatment regimen is divided into an initial phase, lasting two months and a 
continuation phase, lasting four or six months. The initial phase consists of the drugs 
isoniazid, rifampicin pyrazinamide and ethambutol, all having the effect of killing the 
tubercle bacilli rapidly. Within approximately two weeks infectious patients become non-
infectious, symptoms decrease and most of the sputum smear-positive patients become 
smear-negative within two months. The drugs used during the continuation phase are 
fewer but have to be taken for a longer time. They have a sterilizing activity, i.e. they 
eliminate the remaining bacilli and prevent a relapse. Usually, short-course chemotherapy 
consists of a drug combination treatment, i.e. four drugs regimen during the initial phase 
and two drugs regimen during the continuation phase, in order to prevent drug resistance. 
Drug combination treatment is especially important in patients with high bacterial load 
since the risk of developing resistance is increased (WHO/CDS/TB/2003.313).  
 
Re-treatment of tuberculosis patients due to failure, relapse or return after default, have a 
higher chance of drug resistance that might have been acquired during the prior, 
insufficient drug therapy. Those patients are also at high risk of developing MDR-TB 
(WHO/CDS/TB/2003.313).  
 
Treatment of extrapulmonary tuberculosis is, from a public health of view, not of 
significant importance since patients are non-infectious, unless their lungs are infected as 
well (WHO/CDS/TB/2003.313).  
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TB treatment for HIV-infected patients is principally the same as for non-HIV infected 
TB patients. However, it was found that response to tuberculosis treatment and survival is 
better in HIV-infected individuals when RIF was included in the short-course treatment 
(Frieden et al., 2003).  
 
A patient with MDR-TB is defined as having active tuberculosis with bacilli resistant to 
at least rifampicin and isoniazid. It is observed more frequently in re-treatment cases, 
especially in failure cases.  Short-course chemotherapy in MDR-TB patients is ineffective 
and patients need to be treated intensively and for up to 24 months. Treatment of MDR-
TB requires the use of so called second-line antibiotics, which are more expensive and 
often toxic. Second-line drugs include ethionamide, cycloserine, para-aminosalicylic 
acid, quinolones (moxifoxacin, ciprofoxacin), and injectable antibiotics such as amikacin, 
kanamycin or capreomycin. Furthermore, lung resection is frequently needed; although it 
has to be added that in developing countries the facilities for pulmonary surgery are not 
available. In general, the mortality rate among individuals with MDR-TB is high 
(WHO/CDS/TB/2003.313). 
 
Extensively-drug resistance (XDR tuberculosis) has been observed so far only in HIV co-
infected patients. The bacilli are resistant to at least rifampicin and isoniazid, a quinolone 
and one injectable second-line antibiotic (WHO/CDS/TB/2003.313).  
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1.9 Persistence, Latency and Dormancy 
1.9.1 Clinical Aspects 
Despite the ability of M. tuberculosis to generate a productive cell-mediated immune 
response, M. tuberculosis is capable of persisting within the host and to cause a long-term 
asymptomatic (latent) infection. Latency, persistence and dormancy are the terms 
associated with the description of chronic TB (Gomez and McKinney, 2004). 
 
Latency, generally, is a clinical term describing the asymptomatic, chronic stage of a 
human infection. In relation to TB it was defined by Amberson as “the presence of any 
tuberculous lesion, which fails to produce symptoms of its presence”. Latent cases are 
typically PPD-positive by skin test, but are not contagious to others. Without antibiotic 
treatment, a latent infection is thought to be the classic outcome of a TB infection 
(Gomez and McKinney, 2004). 
Given that M. tuberculosis causes a latent infection, it has the ability to persist within the 
host. The manifestation of persistence is due to the capacity of the pathogen to reside 
within macrophages, to avoid elimination by the human hosts immune response and to 
slow the rate of clearance by anti-tuberculosis drugs (Young, 2005).  
Persisting tubercle bacilli may be in a state of dormancy, a term that is described as “a 
reversible state of low metabolic activity, in which cells can persist for extended periods 
without division” (Young, 2005). Important to mention is that dormant bacilli are only 
able to resume growth subsequent to their recovery (Young, 2005). 
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1.9.2 Laboratorial Aspects 
“The question of how bacteria survive for decades in immunologically educated hosts 
without causing disease has puzzled microbiologists for a century” (Stewart et al., 2003). 
The difficulty to define the precise location of persistent bacilli within the host is a 
substantial obstacle to develop and perform in situ studies. Further, the limited 
understanding about the bacterial determinants that allow for persistence, makes it very 
difficult to experimentally recreate the conditions encountered by the pathogen during 
latency. Nonetheless, a variety of in vitro and in vivo systems have been established to 
address the question cited above. Although these systems are limited in their ability to 
fully recapitulate host and bacterial characteristics, they are able to mimic certain aspects 
of latent infection (Young, 2005).  
1.9.2.1 In vivo Models – Cornell Mouse Model and Low-Dose Murine Model 
Cornell Mouse Model. Developed at Cornell University in the 1950s, the Cornell mouse 
model (Figure 1.6) was the first model using a surrogate animal host to display latency of 
tuberculosis. In this model, mice are infected with virulent M. tuberculosis and 
subsequently treated with antimycobacterial drugs. This results in “clinically sterile” 
animal tissue. Albeit clinically sterile, after a three-month period without antibiotics, 
infection resumes in about one third of the mice and the number of relapses is even 
higher when mice are subjected to immunosuppressive therapy (Young, 2005). 
Although this model has the advantage to achieve and maintain low or undetectable 
bacterial number in infected tissues, it is debatable how close this model reflects a human 
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latent infection. This, because anti-tubercular drugs are actually used to achieve latency 




Figure 1.6 | The Cornell mouse model. This model is used to evaluate in vivo persistence of M. 
tuberculosis {Zahrt, 2003 #10}. 
Low-dose Murine Model. The low-dose mouse model (Figure 1.7) stands in contrast to 
the Cornell mouse model since mice are infected with a low-dose inoculum of M. 
tuberculosis. It is an alternative method to recap many characteristics of M. tuberculosis 
during infection. Upon infection, the animals develop a strong cell-mediated immune 
response, leading to the natural formation of persistent bacilli. Furthermore, the mice 
remain competent to reactivation of the disease, either spontaneously or artificially (i.e. 




Figure 1.7 | The low-dose murine model. This model is applied for evaluation of in vivo persistence of M. 
tuberculosis {Zahrt, 2003 #10}. 
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1.9.2.2 In vitro Models – Wayne Model and Nutrient Starvation Model 
The Wayne Non-Replicating Persistence Model. During clinical latency, M. tuberculosis 
possibly resides within granulomatous lesions in the host lung tissue. “The non-
replicating persistence” model (Figure 1.8), developed by Lawrence Wayne, is based on 
the assumption that within these lesions, the bacilli encounter hypoxic or anaerobic 
conditions (Young, 2005). 
In this model, in vitro grown bacteria cultures are subjected to a gradual depletion of 
oxygen thus, adapting to microaerophilic and, eventually, anaerobic conditions in the 
medium. The cells progress through two stages of non-replicating persistence: NRP-1, a 
brief microaerophilic state characterised by cessation of DNA synthesis, and NRP-2, an 
anoxic stationary phase. In this latter phase, bacilli are in a state of oxygen starvation-
induced growth arrest and protein expression is shut down. Synchronous cell division 
occurs after transferring the bacilli into an oxygen-rich medium (Boshoff and Barry, 
2005), (Honer zu Bentrup and Russell, 2001). In the non-replicative state, the bacilli 
exhibit resistance to the drugs isoniazid and rifampicin but become sensitive to 
metronidazole, a drug active against anaerobically growing organisms (Young, 2005). 
 
 
Figure 1.8 | The Wayne non-replicating persistence model. This NRP model system is used to assess 
the growth behavior of M. tuberculosis in hypoxic conditions {Zahrt, 2003 #10}. 
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The Nutrient Starvation Model. The nutrient starvation model (Figure 1.9) was 
established to investigate the effect of nutrients, predicted to be encountered by M. 
tuberculosis in a granuloma, on the bacilli’s metabolism. The model assumes that within 
granulomas, the availability of nutrients and other essential cofactors is likely to be 
limited. For M. tuberculosis it is crucial to metabolically adapt to this environment in 
order to survive and persist.  
The model is initiated by transferring cultures from a nutrient-rich medium to a nutrient-
limiting medium. Subsequently, the cultures are incubated under these conditions for a 
prolonged period. Nutrient starvation results in a gradual decrease of respiration to 
minimal levels, increased resistance to isoniazid and rifampicin, continued resistance to 
metronidazole, an altered colony morphology (cell wall thickening) and altered staining 
properties (loss of  acid fast staining). On a genetic level, a global downregulation in gene 
expression can be observed. The bacilli remain viable and their recovery is observed 
when shifting to rich medium.  
The effect of nutrient starvation on the growth of M. tuberculosis in vivo is presently 
unclear, but changing to secondary metabolism systems might be fundamental in order to 
ensure the survival within host tissues (Betts et al., 2002). 
 
 
Figure 1.9 | The nutrient starvation model. This in vitro model is used to assess the growth 
behavior of M. tuberculosis in nutrient-limiting conditions {Zahrt, 2003 #10}. 
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1.10 Genomics and Proteomics 
1.10.1 Genomics 
The study of mycobacterial genetics has blossomed in recent years due to the 
development of several new genetic approaches and to the DNA sequencing of the M. 
tuberculosis H37Rv genome. Annotation of this genome that consists of 4.4 x 10P6 P base 
pairs and contains around 4000 genes, revealed some unique features. For example, over 
200 genes (i.e. 6% of the total genome) are annotated as encoding enzymes involved in 
fatty acid metabolism, and out of the 200, 100 are predicted to function in the β-oxidation 
pathway. Comparatively, E. coli has only 50 enzymes for fatty acid metabolism (Cole et 
al., 1998), (Smith, 2003). Another distinctive feature is the presence of the unrelated PE 
and PPE families of acidic, glycine-rich proteins, which make up 4% of the entire 
genome (172 genes in total). Similar levels of abundance is also observed in other 
members of the M. tuberculosis complex and further, they are also found in non-
pathogenic mycobacteria. Various of them could be localized in the cell wall and cell 
membrane. In addition, they were shown to be antigenic. Size variation in members of a 
PE subfamily (PE-PGRS subfamily) has been found in clinical TB strains. These data 
suggested that some of the PE and PPE proteins might be involved in antigenic variation 
of M. tuberculosis during infection. However, up to the present their function remain 
unclear (Tundup et al., 2006).  
Nonetheless, most of the in M. tuberculosis annotated groups of genes and their products 
are also found in other microorganisms.  
 
Various new genetic techniques have been invented in order to study the physiology and 
pathogenicity of M. tuberculosis. Current developed methods include gene disruption, 
complementation and antisense methods.  
Gene disruption techniques are divided into directed and global methods, which all result 
in gene inactivation and which all require a selectable marker, usually an antibiotic 
resistance cassette. Directed gene disruption achieves gene inactivation by insertion of an 
antibiotic resistance cassette into the middle of a gene of interest. Subsequently, this 
DNA (linear or circular) is transformed into mycobacteria via electroporation. In the 
course of allelic replacement, the chromosomal gene will be substituted with the mutated 
one (Smith, 2003). In contrast, global gene inactivation entails the insertion of foreign 
DNA (generally a transposable element) into various sites of the bacterial genome. But, 
as for the direct method, only one gene is inactivated.  
Genetic complementation can be used to identify virulence genes of M. tuberculosis. 
Since antisense RNAs reduce specific gene expression, they can also be used for this 
purpose. 
There are other, non-genetic methods, which allow to study the properties of M. 
tuberculosis on a genetic basis. They include reporter gene technology and promoter trap 
systems, hybridization-based methods and proteomics (Smith, 2003).  
1.10.2 Proteomics 
Proteomic tools (e.g. micro array) can be used to measure protein levels during different 
stages of M. tuberculosis infection (e.g. during macrophage infection or during growth on 
fatty acids) and provide global information on gene expression. Two-dimensional gel 
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electrophoresis technology is used to resolve high numbers of proteins and if desired, 
subsequent isolation of the major ones. Further, this technology also allows the 
comparison of protein levels among related samples. In combination with mass 
spectrometry, the proteins can be identified. Determination of individual protein levels on 
a global scale is very important in complementing results from micro arrays, because it 
reflects protein levels, which have undergone posttranslational modification steps. 
Posttranslational modifications can modulate protein levels.  
Further, protein activity can be controlled by covalent modifications. They include 
phosphorylation of two-component systems or activation of DNA binding proteins by 
electrostatic binding of divalent metals (Smith, 2003). 
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PART II 
 
1.11 Biochemistry – Tricarboxylic Acid Cycle 
Most eukaryotic cells and many bacteria are aerobic and oxidise organic fuels such as 
glucose or fatty acids, completely to CO2 and H2O in order to obtain energy. Energy can 
also be produced under anaerobic conditions via fermentation, though this pathway is 
much less efficient in terms of energy production. The molecular processes involved in 
O2 consumption and CO2 formation by cells is called cellular respiration (Berg, 2003). 
 
Cellular respiration can be divided into three major stages. The first stage results in a 
breakdown of organic fuels to yield C2 fragments in form of acetyl coenzyme A (acetyl-
CoA). The second stage is characterised by the activity of the tricarboxylic acid cycle 
(TCA cycle, also termed citric acid cycle or Krebs cycle), which enzymatically oxidises 
the acetyl-CoA molecules produced in the first stage. The energy released by the 
oxidative steps within the cycle is conserved in the reduced electron carriers NADH and 
FADH2. These carriers are oxidized themselves in the third stage of respiration, a process 
defined as oxidative phosphorylation, and release protons (H+) and electrons. The 
electrons are transferred along a chain of membrane proteins, called respiratory chain, to 
O2, which in turn is reduced to H2O. The electron transfer produces a proton gradient 
over the mitochondrial membrane. The protons flow through the ATP-synthase and 
produce ATP from ADP and inorganic phosphate. In prokaryotes, the electron transport 
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system is located in the cytoplasmic membrane since mitochondria are absent (Lehninger, 
1993), (Berg, 2003). 
 
The TCA cycle is the midpoint of a cell’s metabolism and in aerobic organisms, serves in 
both catabolic and anabolic processes (amphibolic pathway). Organic fuels are built up of 
carbon bonds, which lose electrons during oxidative processes. The TCA cycle consists 
of a range of oxidative-reductive reactions that end with the oxidation of an acetyl group 
to COB2 B. Apart from its function in the oxidative catabolism of carbohydrates, fatty acids 
and amino acids, it also provides precursors for many biosynthetic pathways such as for 
amino acids, nucleotides, cholesterol and porphyrin (Lehninger, 1993), (Berg, 2003).  
 
The cycle (Figure 1.10) begins with the condensation of oxaloacetate (CB4 Bunit) with an 
acetyl unit of two carbon atoms to form a citrate (tricarboxylic acid with six carbon 
atoms). An isomer of citrate is converted via two oxidative decarboxylation steps, first 
into α-ketoglutarate (CB5 B unit) and further into succinate (CB4 B unit). From succinate, further 
enzymatic reactions result again in the formation of oxaloacetate. Two carbon atoms 
enter the cycle in form of acetyl-CoA and two carbon atoms leave the cycle in form of 
COB2 B. Three hydride ions (i.e. six electrons) are transferred to three molecules of NAD, 
while a pair of hydrogen atoms (i.e. two electrons) are transferred to one molecule FAD. 
These reactions demonstrate that the role of the TCA cycle consists of gaining electrons 
of high energy from organic fuels (Lehninger, 1993), (Berg, 2003). 
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The TCA cycle, along with the oxidative phosphorylation, deliver the vast majority of 
energy used by aerobic cells, in humans, this is more than 95%. One acetyl unit produces 
approximately ten molecules of ATP. In contrast, anaerobic glycolysis of glucose 
produces only two molecules ATP. The cycle is highly efficient since a minor number of 
molecules produce a big amount of NADH and FADHB2 B. Oxaloacetate, as an example, 
takes part in the oxidation of acetyl groups but gets regenerated itself. This means that 
one molecule of oxaloacetate can take part in the oxidation of many acetyl molecules 
(Lehninger, 1993), (Berg, 2003).  
Acetyl-CoA, which enters the cycle, is derived from the breakdown of fats, amino acids 
and glycogen. Though, breakdown of glycogen in bacteria seems to be found only under 
certain circumstances (Jones et al., 2008). It is of importance in this context to highlight 
pyruvate, produced via glycolysis, which is a significant source of acetyl-CoA. The 
oxidative decarboxylation of pyruvate to acetyl-CoA is the connecting link between 
glycolysis and the TCA cycle (Lehninger, 1993), (Berg, 2003). 
 
Within the TCA cycle only one step will be mentioned here, i.e. the oxidation and 
decarboxylation of isocitrate to α-ketoglutarate, catalysed by isocitrate dehydrogenase 
(ICD). The oxidation produces the first NADH of the cycle. In eukaryotes, isocitrate 
dehydrogenase exists in two forms: as NAD-linked enzyme, found only in mitochondria 
and displaying allosteric properties, and as NADP-linked enzyme that is found in both, 
mitochondria and cytoplasm and showing no allosteric properties (Lehninger, 1993), 
(Berg, 2003). It is believed that in eukaryotes NAD-dependent ICD is involved in the 
TCA cycle. However, it has been hypothesised that NADP-linked ICD might substitute 




Figure 1.10 | The TCA cycle. This cycle begins with the condensation of oxaloacetate and acetyl-
CoA. The subsequent oxidative steps release energy, which is conserved in the reduced electron 
carriers NAD(P)H and FADH2. Apart from ATP production, the cycle provides precursors for many 
biosynthetic pathways. Enzymes are indicated in italic {Munnich, 2008 #46}. 
 
In contrast with eukaryotic systems, most bacteria possess an NADP-linked ICD involved 
in the TCA cycle. Phylogenetic analyses revealed that genomes with only an NAD-
dependent ICD never encode isocitrate lyase (ICL), an enzyme essential for growth on 
acetate. Those with an NADP-dependent ICD do encode ICL. Hence, the NADP 
dependency of prokaryotic ICD appears to be an adaptation to anabolic demand for 
reduced NADP during growth on acetate (Zhu et al., 2005).
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1.12 Escherichia coli and its Behaviour during Growth on Acetate and Fatty 
Acids 
Most pathogenic bacteria are heterotrophs, harbouring the ability to survive on a series of 
different carbon substrates such as carbohydrates, lipids, glycolipids, dicarboxylic acid 
and amino acids. Carbon catabolism supplies the bacterial cell, not only with energy in 
form of reducing agents and ATP, but also with intermediates, including acetyl-CoA, 
propionyl-CoA and oxaloacetate, all of which are fundamental for biosynthesis. The 
preferred carbon and energy source for many bacteria are hexoses. There are different 
pathways, which result in catabolism of these sugars. Glycolysis and pentose phosphate 
pathway are among the best characterised (Munoz-Elias and McKinney, 2006).  
1.12.1 Growth on Acetate and Fatty Acids 
In E. coli, when acetate is the sole source of carbon and energy, it first has to be 
converted into acetyl-CoA. In this form it becomes usable for replenishing intermediates 
of the TCA cycle via the glyoxylate shunt, which constitutes the dominant anaplerotic 
pathway (Munoz-Elias and McKinney, 2006). In comparison, in humans, acetate cannot 
be converted directly to acetyl-CoA, but is introduced into the metabolic pathways that 
lead to the production of pyruvate.  
Degradation of fatty acids is directed via the β-oxidation cycle and results in their 
complete conversion into either acetyl-CoA or propionyl-CoA, depending on the nature 
of the fatty acids. As a consequence, bacteria are able to grow on fatty acids as sole 
source of carbon by operating through the same pathways as those required for growth on 
acetate (Cozzone, 1998).  
Upon degradation of fatty acids, ATP is formed via production of FADH2 and NADH. In 
contrast, the conversion of acetate to acetyl-CoA does not produce ATP and thus, growth 
on fatty acids is energetically more favourable per carbon atom than growth on acetate 
(Cozzone, 1998).  
1.12.2 Glyoxylate Shunt 
Plants, certain invertebrates and some microorganisms such as E. coli and M. 
tuberculosis use for energy production and for biosynthesis a metabolic pathway called 
glyoxylate pathway (also dubbed glyoxylate shunt or glyoxylate bypass). When acetate or 
fatty acids are the sole carbon source, the operation of the glyoxylate cycle as an 
anaplerotic pathway is required (Wendisch et al., 2000). The reason behind is that for 
each molecular unit of acetate that enters the TCA cycle, two molecular units of CO2 are 
lost. By this mean, no net assimilation of carbon can occur and therefore, growth on 
acetate or fatty acids implicitly need this separate pathway to enable biosynthesis of 
cellular components (Cozzone, 1998). The bypass also provides some energy since it 
involves two oxidative steps. Nonetheless, most energy is derived from the TCA cycle 
and whenever there is access to a more easily metabolisable carbon source, the glyoxylate 
shunt is turned off, because of catabolite repression (Cozzone, 1998).  
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1.12.3 Regulation of the Shunt 
Upon growth on acetate, the two unique enzymes of the glyoxylate bypass, isocitrate 
lyase (ICL) and malate synthase (MAS) are induced. The former enzyme catalyzes the 
aldole cleavage of isocitrate to succinate and glyoxylate. It thus bypasses the two steps in 
the TCA cycle, in which carbon is lost in the form of CO2 (Cozzone and El-Mansi, 2005). 
The catalytic condensation of acetyl-CoA and glyoxylate by MAS leads to the formation 
of malate and free-CoA, thus fulfilling its anaplerotic function (Cozzone and El-Mansi, 
2005). To note is that both, succinate and malate, are intermediates of the TCA cycle and 
hence, lead to the production of oxaloacetate. Oxaloacetate can be converted into 
phosphoenolpyruvate, which serves as a precursor of glucose and gluconeogenesis (Berg, 
2003). 
 
Figure 1.11 | The glyoxylate shunt. This 
pathway is mobilised when bacteria are 
grown on acetate or fatty acids. Whether the 
carbon flux is directed into the glyoxylate 
shunt or continues in the TCA cycle is 
determined at the branch point. There, 
isocitrate lyase and isocitrate dehydrogenase 
compete for their common substrate, 
isocitrate. It is believed that the glyoxylate 
shunt is the first step that directs the carbon 
flux into gluconeogenesis. This is the only 
way, by which the bacteria can acquire and 
retain carbon from acetate or fatty acids 
{Russell, 2001 #64}. 
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The TCA cycle and the glyoxylate bypass are coordinately regulated. When bacteria are 
grown on acetate or fatty acids, ICL is in direct competition with ICD for their common 
substrate isocitrate. It was shown that mutants deficient in isocitrate lyase are unable to 
grow on acetate. Control of the glyoxylate bypass concerns the increased expression of 
ICL, which is accompanied by modulation of ICD activity through a reversible 
phosphorylation (Cozzone, 1998).  
1.12.4 Isocitrate Dehydrogenase 
Isocitrate dehydrogenases, also known as ICDs, are a large, ubiquitous, and very ancient 
family of enzymes that play a central role in the TCA cycle. As mentioned earlier, most 
ICD family members require NAD for substrate oxidation, but yet most bacteria 
including E. coli, use NADP instead. Bacteria with NAD-dependent ICDs are unable to 
grow on acetate, in contrast to bacteria with NADP-dependent ICDs. NADP dependence 
appears to be an adaptation of the bacteria to grow on acetate. It is important to note that 
all enzymes require an integrated Mg2+ or Mn2+ ion and that most of them are dimers, 
specifically homodimers (Cozzone, 1998), (Zhu et al., 2005). 
Bacterial ICDs show similarity in structure and function. This led to the assumption that 
the structure and the active site among most prokaryotic ICDs is conserved. Eukaryotic 
NADP-dependent ICDs have been shown to have diverse important biological functions; 
however, their regulatory mechanism remains unclear (Yasutake et al., 2003). 
Each dimer ICD has two active sites and each of them binds a NAD+/NADP+ molecule 
and a Mg2+ or Mn2+ metal-ion. Within the active site, isocitrate binds through the 
formation of hydrogen bonds to a conserved sequence of about eight amino acids. Mg2+ 
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or Mn2+ binds to three aspartate residues through hydrogen bonds. NAD+/NADP+ binds 
four regions within the active site. Although these regions may vary among ICDs, their 
properties are similar (Fedoy et al., 2007). 
 
E. coli has only one NADP-linked, Mg2+ dependent ICD, consisting of two identical 
subunits with a molecular mass of about 45 kDa per subunit. Sequencing of the 
corresponding gene icd showed that the enzyme has no significant sequence homology 
with other ICDs or nucleotide binding proteins. Further, investigation of the intracellular 
localization of ICD showed its dispersion in the cytoplasm (Yasutake et al., 2003). 
1.12.5 Reversible Phosphorylation 
The inactivation of ICD by reversible phosphorylation was first observed in a study, 
where acetate was added to a stationary phase culture of E. coli in glycerol medium 
containing 32P-labeled orthophosphate. The result was a rapid loss of ICD activity 
associated with incorporation of radioactivity into the enzyme.  
Further, it was shown that when bacteria are grown on acetate, about 75% of ICD is 
inactivated by phosphorylation and that the phosphorylated form of ICD is completely 
inactive. The inactivation of the enzyme forces isocitrate through the glyoxylate shunt 
and reroute some of the carbon flux from the TCA cycle. This form of regulation is 
necessary since ICL has a much lower affinity for isocitrate (Km = 604 µM) than does 
ICD (Km = 8 µM). Inhibition of ICD restricts the flux through the TCA cycle and allows 
the intracellular concentration of isocitrate to rise to a level, high enough to assure the 
flux through isocitrate lyase .  
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Dephosphorylation of ICD, as for example through addition of glucose to an E. coli 
culture grown in acetate medium, leads to the inhibition of the glyoxylate shunt. The 
explanation here is that the enzyme recovers the capability to bind isocitrate and so 
directs the carbon flux through the TCA cycle. By doing so, the isocitrate pool declines 
considerably. This decreases the probability that isocitrate lyase binds to isocitrate.  
Concerning growth, it is important to mention that a precise balance between the two 
competing cycles is essential (Cozzone, 1998).  
1.12.6 Mode of Inactivation 
Inactivation and reactivation of ICD is achieved by phosphorylation and 
dephosphorylation of its amino acid residue serine 113. Phosphorylation prevents 
isocitrate from binding to the active site, because hydrogen bonds cannot form between 
the substrate and the enzyme. Further, the binding is inhibited by the negatively charged 
phosphate group of serine 113, which creates an electrostatic repulsion towards the 
negatively charged γ-carboxylate of isocitrate (Cozzone and El-Mansi, 2005).  
It was suggested that ICD changes its conformation upon phosphorylation since it was 
found that the phosphorylated form of ICD was much less susceptible to proteolysis than 
the native form (Cozzone and El-Mansi, 2005).  
1.12.7 Isocitrate Dehydrogenase Kinase/Phosphatase 
Isocitrate dehydrogenase kinase/phosphatase (ICDK/P) is the bifunctional enzyme that 
catalyses both, the phosphorylation and the dephosphorylation of ICD (Miller et al., 
2000). Only one active site has been found on the enzyme and ICD is the only substrate 
recognized by ICDK/P. Its activity determines the amount of phosphorylated, and thus 
inactivated, ICD. Inactivation of ICD is thought to facilitate the flux through ICL since 
the affinity of ICL for isocitrate is much lower in comparison to ICD. In other words, the 
higher the concentration or activity of ICDK, the more ICD is phosphorylated/ 
inactivated. This lowers the carbon flux through ICD and therefore, leads to a higher 
concentration of intracellular isocitrate. The high concentration of isocitrate increases the 
chance of ICL binding to isocitrate and thus, directs the carbon flux into the glyoxylate 
shunt. In summary, it is believed that ICDK/P controls the partitioning of the carbon flux 
at this particular branch point by phosphorylation/dephosphorylation of ICD (Cozzone 
and El-Mansi, 2005).  
Interestingly, studies using mathematical models revealed that ICD is not the “rate-
controlling” step during growth on acetate. Above a certain threshold concentration of 
ICL, the TCA cycle and the glyoxylate shunt work in concert without need for ICD 
phosphorylation or dephosphorylation. It is thought that the role of ICDK/P is to facilitate 
the flux through ICL by inactivating approximately 75% of total ICD (Cozzone, 1998).  
1.13 Insight into the Metabolism of Mycobacterium tuberculosis 
1.13.1 Metabolic Flexibility 
With the onset of cell-mediated immunity along with the activation of macrophage 
antimicrobial mechanisms and  the appearance of the mycobacterial vacuole as a nutrient-
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poor compartment, M. tuberculosis faces a very hostile environment.  It seems probable 
that survival under these harsh circumstances might lead to changes in M. tuberculosis 
metabolic pathways and the therein occurring substrates. Unfortunately, the metabolic 
alterations during the process of infection are largely unknown (Munoz-Elias and 
McKinney, 2006).  
Nevertheless, M. tuberculosis behaves like most other bacteria with regard to 
carbohydrate metabolism, energy production and biosynthesis of intermediates for 
macromolecules (Wheeler Paul R., 1994). The prototrophic feature and metabolic 
flexibility of M. tuberculosis permit the bacilli to oxidize a variety of carbon substrates 
such as sugars, tricarboxylic acids (e.g. citric acid), fatty acids and amino acids (Munoz-
Elias and McKinney, 2006). The findings that this bacterium can be grown on a wide 
range of carbon compounds in laboratories implies that when acting as a pathogen within 
host tissues, it also might be able to assimilate a range of host tissue metabolites for its 
own purpose, notably the assimilation of the many glycans and lipids characteristic for 
mycobacteria (Wheeler Paul R., 1994), (Wheeler, 2005). 
1.13.2 Gene Redundancy 
Findings based on genetic analysis revealed that throughout the entire metabolism of M. 
tuberculosis more than one gene is predicted for a certain function. This gene redundancy 
or paralogy is apparent for instance for phosphofructokinase, citrate synthase, isocitrate 
dehydrogenase, pyruvate dehydrogenase, isocitrate lyase and lactate dehydrogenase 
(Wheeler Paul R., 1994), (Wheeler, 2005). Gene redundancy in M. tuberculosis may 
reflect an ability to survive and grow in very different environments within the host. As 
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example, one compares the centre of a caseous lesion with an active, alveolar 
macrophage. In contrast, it has been suggested that the loss of redundancy in the M. 
leprae genome reflects a specialized “life-style” (Wheeler, 2005). 
1.13.3 THE Carbon Source 
Host lipids appear to be the primary carbon source for M. tuberculosis in vivo during 
infection (Figure 1.12). This is further supported by the findings that i) bacteria harvested 
from infected tissues preferentially metabolize fatty acids over carbohydrates, and ii) the 
icl-1 and icl-2 genes, which were shown to be essential when lipids are the sole source of 
carbon, are required for growth in vivo (Jain et al., 2007). 
1.13.4 Fatty Acids  
Although during growth in vitro, M. tuberculosis rapidly metabolises glucose and 
glycerol from the medium (Figure 1.12), emerging evidence implies that during infection 
fatty acids are the dominant carbon substrates (Boshoff and Barry, 2005a). If so, this 
could explain the high abundance of genes (>150) found in the genome of M. 
tuberculosis, which encode for enzymes involved in the pathway of β-oxidative fatty acid 
degradation (Honer zu Bentrup and Russell, 2001). Further, it was shown that bacteria 
isolates from lungs of chronically infected mice preferentially oxidized fatty acids (Bloch 
and Segal, 1956). Also, analysis of genome sequences revealed an extensive gene 
redundancy for genes encoding enzymes of fatty acid degradation and further, their 
upregulation during infection of macrophages and mice (Munoz-Elias and McKinney, 
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2006). 36 homologues of fadE genes (encoding the fist step of the β-oxidation pathway) 
and 36 paralogues of fadD (encoding acyl-CoA ligase) were found. These genes together 




Exogenous lipids, in general, can have a big impact on the cell’s economy since the 
amount of lipids available for assimilation is in excess compared to the quantity of 
carbohydrates. This, together with the bacilli’s ability to simultaneously catabolise and 
anabolise fatty acids and the detection of lipolytic enzymes supported the view, of M. 
Figure 1.12 | Major pathways of biosynthesis in M. tuberculosis. The glucose-based routes are 
believed to function during growth of M. tuberculosis in vitro, whereas the lipid based routes are 
believed to be the ones encountered in vivo. Black arrows highlight pathways that generate reducing 
equivalents; violet arrows indicate reactions that replenish TCA and glyoxylate cycles intermediates; 
blue arrows show gluconeogenetic and biosynthetic pathways; red arrows show the glyoxylate shunt. 
This pathway replenishes both, intermediates of the TCA cycle and the glyoxylate shunt itself. The 
blocks highlight the different cellular components that are biosynthesised via the different biosynthetic 
pathways {Boshoff, 2005 #47}. 
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tuberculosis being rather lipolytic than lipogenic. Repression, like in this case the 
repression of lipid synthesis enzymes, is also predicted for enzymes involved in 
biosynthesis of amino acids, fatty acids, purines and pyrimidines, as they can all be 
supplied from the host (e.g. blood plasma). Nevertheless, M. tuberculosis still has the 
ability to synthesis all metabolites from one specific carbon source since it isn’t an 
obligate intracellular pathogen and since, under laboratory conditions, it is able to grow 
on only one carbon substrate (Wheeler Paul R., 1994), (Wheeler, 2005). 
1.13.5 The Influence of the Immune System 
Carbon source utilisation seems to depend on the immune status of the host. The onset of 
acquired immunity two weeks after infection, which leads to IFN-γ dependent activation 
of macrophages, encounters the bacilli with a change of environment in the lungs. 
Nutrient starvation within the phagosome forces the bacilli to shift their primary carbon 
source to fatty acids, which are present in the endosomal-lysosomal network of the host 
cell. Genes involved in β-oxidation, glyoxylate shunt and gluconeogenesis are found to 
be induced during survival within the phagosome of activated macrophages (Boshoff and 
Barry, 2005b).  
Concomitant with the finding that the ability to adopt a persistent phenotype involves a 
metabolic shift in the carbon source used by M. tuberculosis, McKinney et. al (Munoz-
Elias and McKinney, 2005) established that the two isoforms of ICL are jointly required 
for bacterial growth and persistence in activated macrophages and mice. Along with the 
upregulation of the icl gene, phosphoenolpyruvate carboxykinase gene pckA, a gene 
encoding for an important enzyme of gluconeogenesis pathway, was also found to be 
upregulated (Boshoff and Barry, 2005b). Increased levels of ICL expression were shown 
to correlate directly with the activation status of the macrophage. Deletion of icl-1 or icl-
2 attenuated bacterial persistence and virulence in mice, but showed little effect on 
bacterial growth in macrophages and mice during the acute phase of infection. However, 
deletion of both, icl-1 and icl-2 genes, resulted in a complete impairment of intracellular 
replication in activated (but not in resting) macrophages and a rapid elimination from the 
lungs (Munoz-Elias and McKinney, 2005).  
1.13.6 At the Branch Point between the Glyoxylate Shunt and the TCA cycle 
The glyoxylate shunt is, as already described earlier, a secondary metabolic pathway, 
which allows the bacteria to utilise fatty acids (i.e. C2 substrates) in times when primary 
carbon sources are limiting, as for instance in the phagosome, and the generation of 
pyruvate from glycolysis is reduced. The net incorporation of carbon replenishes the 
concentration of the two intermediates, succinate and malate, which have the overall 
effect of maintaining oxaloacetate levels. The production of oxaloacetate via pyruvate is 
restricted due to limitation in carbohydrate availability. The upholding of oxaloacetate 
levels permits acetyl-CoA to continuously enter the TCA cycle and this in turn ensures 
the maintenance of the cycle (Gould et al., 2006).  
 
The branch point between the glyoxylate shunt and the TCA cycle shows differences 
comparing E. coli and M. tuberculosis. Some characteristics are described below. 
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1.13.7 Isocitrate Dehydrogenase  
The Mycobacterium tuberculosis genome has two isoforms of isocitrate dehydrogenase. 
The two isoenzymes only share around 14% identity at amino acid level. M. tuberculosis 
ICD-1 is more similar to eukaryotic NADP-dependent ICDs, whereas M. tuberculosis 
ICD-2 groups with prokaryotic ICDs. Little is known so far about their enzymatic 
properties (Banerjee et al., 2005).  
As in E. coli, M. tuberculosis isocitrate dehydrogenase is said to allosterically regulate 
the conversion of oxidative decarboxylation of D-isocitrate to α-ketoglutarate and COB2 B in 
presence of a cofactor and a metal ion. ICD-1 is a homodimer. ICD-2, although annotated 
as a monomer, is present in higher oligomeric forms, the dimer being the most stable one 
(Banerjee et al., 2005).  
Furthermore, it was found that both genes encode functional TCA cycle enzymes with 
identical enymatic function but different physio-chemical and kinetic properties. They 
differ in their affinity for coenzyme NADP, pH tolerance and thermostability (Banerjee et 
al., 2005). By comparing VBmax B(NADP)/KBmB(NADP) ratios for the two enzymes, ICD-2 
was shown to be the more efficient one. ICD-1 was shown to be more robust in terms of 
pH tolerance and thermostability. Overall, these findings suggest that even with identical 
metabolic function, expression of the two ICDs could be differential during different 
stages of growth (Banerjee et al., 2005).  
Using a pathway modelling system, it has been demonstrated that flux through the 
glyoxylate shunt was only allowed when both, ICD-1 and ICD-2, were more than 70% 
inactivated. In absence of ICL-1, more than 90% inactivation of the two enzymes is 
required (Singh and Ghosh, 2006). 
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1.13.8 Homologue of E. coli Isocitrate Dehydrogenase Kinase/Phosphatase 
ICDK/P has been found neither for M. tuberculosis ICD-1 nor for ICD-2. Since ICDK/P 
in E. coli was shown to be a serine protein kinase/phosphatase, it seemed reasonable to 
examine the genome of M. tuberculosis for such enzymes. So far, 11 predicted 
eukaryotic-like serine/threonine protein kinases (STPKs) and one serine/threonine 
phosphatase (PstP) were found. Nine of them are predicted as transmembrane receptors. 
Initial studies have established roles for the STPKs in prokaryotic development, stress 
response and host-pathogen interactions. The metabolic functions, as well as the 
molecular mechanisms of Ser/Thr phosphorylation systems in M. tuberculosis, are 
hitherto unknown (Greenstein et al., 2005).  
1.13.9 The Role of Isocitrate Lyase 
The genome of M. tuberculosis apparently has two isoforms of isocitrate lyase, whereby 
the smaller gene icl-1 encodes an enzyme closely related to isocitrate lyase in other 
eubacteria; the larger gene icl-2 encodes an enzyme homologous to eukaryotic isocitrate 
lyases (Munoz-Elias and McKinney, 2005).  
Gould et. al predicted a dual role for ICL-1; of it being involved in the glyoxylate shunt, 
as well as in the methylcitrate cycle. β-oxidation of even-chain fatty acids results in the 
production of acetyl-CoA, whereas β-oxidation of odd-chain or branched-chain fatty 
acids and also branched chain amino acids produces propionyl-CoA. High levels of either 
propionate or propionyl-CoA are toxic for bacteria and fungi. Two putative pathways, 
methylmalonyl-CoA pathway and methylcitrate cycle, were found in M. tuberculosis that 
might ensure the metabolism of these two intermediates. This would circumvent their 
accumulation. 
In E. coli, the methylcitrate cycle is the principal pathway for clearance of propionyl-
CoA during growth on propionate. The methylcitrate cycle metabolises propionyl-CoA to 
pyruvate, possibly preventing propionate toxicity and also providing another pathway for 
carbon anaplerosis during growth on odd/branched-chain fatty acid substrates (Gould et 
al., 2006). The recent observation that ICL-deficient tubercle bacilli were unable to grow 
on propionate led to the hypothesis that these enzymes might have a dual role in the 
metabolism of fatty acids. They might participating as ICLs in the glyoxylate shunt and 
as MCLs (2-methylisocitrate lyase) in the methylcitrate cycle. This view is supported by 
the finding that M. tuberculosis possesses homologues for two of the three enzymes 
involved in the methylcitrate cycle. Homologues were found for methylcitrate synthase 
and methylcitrate dehydrogenase but not for MCL. Gould et. al demonstrated recently 
that the active site of M. tuberculosis ICL1 bound to pyruvate and succinate can 
accommodate the additional methyl group of 2-methylisocitrate and catalyse the MCL 
reaction (Gould et al., 2006). 
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1.14 Aims of the Project 
This project was based on the purpose of better understanding the regulation of the 
branch point between the glyoxylate shunt and the TCA cycle by finding the so far 
unknown, putative M. tuberculosis isocitrate dehydrogenase kinase/phosphatase. In this 
context, we also tried to gain insight into the nature of ICD-1 and ICD-2 and their 
phosphorylation status based on the particular carbon substrate present in the growth 
medium. Obtaining a better understanding of this particular branch point is of major 
importance since fatty acids are believed to be the main source of carbon and energy for 
M. tuberculosis in chronically infected animals and also in humans. Furthermore, the 
glyoxylate bypass was shown to be crucial for E. coli and M. tuberculosis during growth 
on acetate or fatty acids. 
 
During the course of this project we pursued the following goals: 
 
i) Understanding the regulation of the branch point.  
 
ii) Finding of the yet unknown, putative isocitrate dehydrogenase 
kinase/phosphatase in BCG. 
 
iii) Purifying ICD-1 and ICD-2 and assure their activity. The purified proteins 
were thought to be in later use for the confirmation of the expected role of the 
putative kinase/phosphatase. 
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iv) Constructing a modified version of E. coli isocitrate dehydrogenase, which 
would not allow phosphorylation of its gene product in BCG. This construct 
would possibly show phenotypic differences when grown in either glucose or 
acetate and therefore allow predictions for the regulation of the bypass by the 
putative kinase/phosphatase.  
 
v) Gaining insight into the nature of ICD-1 and ICD-2 by creating knockout 
mutants and characterise their phenotypes under different conditions. This 
would eventually reveal functional differences between the two isocitrate 
dehydrogenases and further, specify the expected role of the putative kinase. 
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Materials & Methods 
2.1 Materials 
2.1.1 Strains  
Mycobacterium bovis bacillus Calmette-Guérin (#35734), henceforth stated as BCG, was 
obtained from the American Type Culture Collection (ATCC). E. coli Tuner (DE) cells 
were obtained from Novagen. E. coli TOP10 cells were obtained from Invitrogen. The E. 
coli strains JM109 and BMH 71-18 mutS were part of the GeneEditor in vitro Site-
Directed Mutagenesis System kit from Promega. The human lung adenocarcinoma cell 
line (A549) was purchased from ATCC.  
2.1.2 Media  
E. coli cells were routinely propagated in Luria-Bertani (LB) broth (Becton Dickinson), 
or onto LB agar plates. BCG was propagated in Middlebrook 7H9 medium (Becton 
Dickinson), supplemented with 0.05% Tween-80, 0.5% bovine serum albumin (Roche; 
#10711454001), 0.081% NaCl, 0.2% glycerol and 0.2% glucose, or onto Middlebrook 
7H11 agar plates.  
For growth of E. coli the medium was, if necessary, supplemented with kanamycin (50 
µg/ml), hygromycin (150 µg/ml), ampicillin (100 µg/ml), X-gal (40 µg/ml). For growth 
of BCG, the medium was, if required, supplemented with kanamycin (25 µg/ml), 
hygromycin (75 µg/ml), X-gal (40 µg/ml), sucrose (2% v/v). Ampicillin, kanamycin and 
X-gal were obtained from Sigma-Aldrich, hygromycin was obtained from Roche and 
sucrose from FisherScientific. 
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Human lung adenocarcinoma cells (A549) were cultured in filterised THP-1 growth 
medium, containing RPMI, heat-inactivated FBS (10% final concentration), glutamax I 
(10 mM final concentration), sodium pyruvate (1 mM final concentration), D-Glucose, 
anhydrous (1.25mg), 2-mercaptoethanol (0.05 mM final concentration), penicillin-
streptomycin (10,000 U/ml penicillin and 10,000 µg/ml streptomycin); all components 
were from GIBCO). 
2.1.3 Culture Conditions in a Defined Carbon Source  
Middlebrook 7H9 medium was used as BCG culture medium with glycerol as main 
carbon source. BCG culture medium with glucose as a sole source of carbon consisted of 
7H9 base (i.e. 7H9 broth with 0.05% Tween-80), supplemented with 0.2% glucose, 
0.08% NaCl and 0.05% fatty acid-free BSA (BSA-FAF; Sigma Aldrich, #A8806). 
Alternatively, when acetate was the sole source of carbon, the culture medium consisted 
of 7H9 base, 0.2% sodium acetate, 0.08% NaCl, 0.05% BSA-FAF. For shifting BCG 
from complete 7H9 medium to glucose or acetate medium, the cells had to be washed 
twice by centrifugation (3000 rpm, 10 min, RT) with 7H9 base and resuspended in 7H9 
base. The OD was measured and the cells inoculated into glucose or acetate medium. 
Starting OD600 was 0.02.  
BCG culture medium without glutamic acid consisted of 7H9 base deprived of glutamic 
acid, supplemented with 0.1% sodium acetate, 0.1% glycerol, 0.08% NaCl, 0.1% BSA-
FAF. Additionally, this medium was supplemented with 0.1% glutamic acid if growth in 
presence of glutamic acid was examined.  
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2.1.4 Materials for Purification of M. tuberculosis ICD-1 and ICD-2 
Gateway LR Clonase Reaction (Invitrogen); Bug Buster Protein Extraction Reagent 
(Novagen); Lysonase Bioprocessing Reagent (Novagen); Ni2+-nitrilotriacetate affinity 
chromatography spin columns (Ni-NTA spin column from Qiagen); millipore membrane 
filter (Sartorius); immobilised metal affinity chromatography column (IMAC column 
from Qiagen); Ni-NTA His-Bind agarose (Qiagen); Econo-Column flow adaptor (Bio-
Rad); Econo-Gradient pump (Bio-Rad); Bradford protein assay (Bio-Rad), ultrafiltration 
spin columns (Vivaspin 10K and 30K MWCO; Sartorius Group); PD-10 column (GE 
Healthcare); PreScission Protease (Novagen); prepacked XK column designed for 
preparative gel filtration chromatography separations, Superdex 200 (Mr 10,000-600,000) 
10/300 GL; 25 ml/CV (GE Healthcare); UNICORN software program for control and 
supervision of chromatography (GE Healthcare). 
2.1.5 Materials for Western Blotting and Immunodetection 
Immuno-blot PVDF Membrane for Protein Blotting (Bio-Rad); Phospho-threonine 
(isotype mouse IgG1) and phospho-serine (isotype mouse IgG1 and IgM) antibody 
(Qiagen); Alkaline phosphatase-conjugated AffiniPure Rabbit Anti-Mouse IgG + IgM 
(H+L) antibody (Jackson ImmunoResearch); BCIP/NBT-Blue Liquid substrate for 
membranes (Sigma-Aldrich).  
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2.1.6 Materials for Molecular Cloning  
All restriction enzymes and the corresponding buffers were purchased from New 
Englands BioLabs; dNTPs (New England BioLabs); TAE buffer and ethidium bromide 
(Bio-Rad); plasmid vector pCR2.1-TOPO (Invitrogen); membrane filter for micro 
dialysis (Millipore, Sartorius Group); shrimp alkaline phosphatase (Roche); Gene Pulser 
cuvette and Gene Pulser Xcell (Bio-Rad); PETG Media Bottles (Nalrgene); DMSO 
(Acros Organics). 
 
2.1.7 Materials for Crude Cell Extraction, Growth Assays, MIC50 Assays and Enzyme 
Assays  
Protease inhibitor cocktail tablet, EDTA-free (Roche); glass beads and Mini Beadbeater 
(Biospec Products); the compounds Isoniazid, 3-Nitropropionate, DL-isocitrate and 
NADP were purchased from Sigma-Aldrich, NADPH was purchase from Merck; T25 
flasks (Nalge Nunc). 
2.1.8 Other Materials  
SDS-PAGE was performed using NuPAGE Novex 4-12% Bis Tris mini gel 1.0 mm, 
along with the corresponding MES and MOPS buffer for PAGE. Novex Sharp Protein 
Standard was used as marker. Gels, buffers and the marker were purchased from 
Invitrogen. For subsequent Coomassie Blue staining Bio-safe Coomassie Blue from Bio-
Rad was used. 
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Chemicals, which were used in the experiments, but are not mentioned in this Chapter by 
name, were either obtained from Sigma-Aldrich, Merck or FisherScientific.  
NCBI (National Centre for Biotechnology Information) and TuberuList BLAST (Basic 
Local Alignment Search Tool program) programs, software program GraphPad Prism, 
version 4 for Windows.  
2.1.9 Kits  
Protein concentrations were determined by using the Protein Quantification Kit from 
Pierce (BCA Protein Assay Reagent Kit). The ProteoEnrich ATP-Binders Kit from 
Novagen was implemented for enrichment of ATP-binding proteins (ABPs) such as 
kinases. The Phosphoprotein Purification Kit from Qiagen was used to purify 
phosphoproteins. Further it was used for crude cell extraction of the cell line A549 and as 
a modified version for crude cell extraction of ABPs. The kit GeneEditor in vitro Site-
Directed Mutagenesis System from Promega was used to introduce a point mutation into 
E. coli icdopt gene. Plasmid DNA was purified using the QIAprep Spin Miniprep Kit from 
Qiagen. PCR samples were mixed with reagents from the Hot Star Taq Plus DNA 
Polymerase Kit from Invitrogen. PCR products were purified after gel electrophoresis 
with the PCR Purification Kit from Qiagen. The TOPO TA Cloning Kit from Invitrogen 
was used for subcloning of the knockout constructs into E.coli TOP10 cells. Purification 
of plasmids and inserts from agarose gels was carried out using the Gel Extraction Kit 
from Qiagen. Plasmid and insert ligation was carried out using Rapid Ligation from 
Roche. 
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2.2 Methods 
2.2.1 Enrichment of ATP-Binding Proteins  
In order to find the yet unknown kinase of wt BCG, which eventually phosphorylates 
ICD-1 and/or ICD-2, the ATP-Binders Kit was implemented. This kit is designed for 
enrichment of eukaryotic protein extracts with ABPs such as protein kinases.  
Crude cell extraction was performed with pellets of wt BCG, which had been grown on 
glucose and on acetate. For the procedure a modified version of the protocol from the 
Phosphoprotein Purification Kit was used: The cell pellets were washed in PBS 
containing 0.05% Tween-80 in order to remove BSA. Next, they were resuspended in 5 
ml lysis buffer containing CHAPS, 1 protease inhibitor tablet (1 tablette/50 ml) and 
benzonase (all provided by the kit). The cultures were bead beated at 4ºC, followed by 
centrifugation (10,000 g, 5 min, 4ºC). The supernatants were removed and centrifuged 
again (10,000 g, 30 min, 4ºC). In order to remove free endogenous ATP, extracts were 
dialysed, using a PD-10 column, in PBS containing 1 mM EDTA and 1 mM DTT. The 
crude cell extracts were loaded onto spin filters containing ATP-Binders resin, i.e. a 
polyacrylamid-based resin on which ATP is immobilized at the γ-phosphate. The resin 
has a high affinity for ABPs. The enrichment of ABPs was carried out according to the 
instructions of the manufacturer. For visualizing of the eluted ABPs a SDS-PAGE, 
followed by silver staining was performed. For silver staining the following reagents and 
solutions were used: fixing solution (40% methanol, 10% acetic acid); 0.02% sodium 
thiosulfate (NaB2 BSB2 BOB3 B); 0.1% silver nitrate (AgNOB3 B); developing solution (3% sodium 
carbonate, 0.05% formalin); 5% acetic acid. 
2.2.2 Purification of Phosphoproteins 
For characterisation of the phosphorylation status of Ser/Thr sites of wt BCG ICD-1 and 
ICD-2, the Phosphoprotein Purification Kit was used. This kit is designed for specific 
purification of phosphorylated proteins from eukaryotic cell lysates.  
The experiment was carried out using glucose and acetate grown wt BCG. Additionally, 
the experiment was carried out with eukaryotic cell extracts from A549 cells. After crude 
cell extraction, lysates containing approximately 2.5 mg of total protein were taken and 
added to an affinity column, which bound the phosphorylated protein. The flowthrough 
was collected for analysis of unphosphorylated protein, the eluate fractions were used for 
analysis of phosphorylated protein.  
 
Western transfer of the different fractions was carried out using a protocol from Qiagen 
(QIAexpress Detection and Assay Handbook). Blotting of a PVDF membrane was 
carried out in tank-blotting transfer buffer (25 mM Tris base, 150 mM glycine, 20% 
ethanol, pH 8.3) at 4ºC, 120 V, 400 mA, 1 hour.  
For immunodetection the following buffers were used: TBS-Tween buffer [10 mM Tris-
HCl, 150 mM NaCl, 0.1% (v/v) Tween-20, pH 7.5]; blocking buffer [(1.8 g BSA/60 ml 
TBS (10 mM Tris-HCl, 150 mM NaCl, pH 7.5)]; TBS-Tween/Triton buffer [(20 mM 
Tris-HCl, 500 mM NaCl, 0.05% (v/v), Tween-20, 0.2% (v/v) Triton X-100, pH 7.5)]; 
TBS-Tween buffer containing 0.1% BSA. The membrane was incubated with a phospho-
threonine and phospho-serine antibody solution (1/100 dilution) at 4ºC, ~20 rpm, o/n. 
AP-conjugated Anti-Mouse antibody (1/8000 dilution) was used as secondary antibody. 
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Incubation was allowed for 1 hour at RT. BCIP/NBT-Blue was used for detection. 
Catalytic conversion of BCIP/NBT was allowed for up to 30 min.  
2.2.3 Expression and Purification of M. tuberculosis ICD-1 and ICD-2 in E. coli 
2.2.3.1 Small Scale Purification  
Gateway LR Clonase Reaction was performed with an in-house entry vector containing 
the gene icd-1 or alternatively icd-2, and an in-house destination vector containing one 
out of eight different N-terminal 6xHis sequence tags. The generated constructs were 
transformed into E. coli Tuner (DE3) cells. Colonies from each construct were first 
precultured in LB medium containing kanamycin, then transferred (1/100 dilution) into 
LB medium containing kanamycin and grown until OD600 of 0.6-0.8. The cells were 
cooled to 18ºC and temperature equilibrated for 30 min. Induction of protein expression 
by addition of 0.1 mM IPTG was allowed to proceed o/n at 18ºC, 200 rpm. Cells were 
harvest by centrifugation at 3,000 g for 10 min. The pellet of each construct was 
resuspended in 1 ml Bug Buster Protein Extraction Reagent that had been premixed with 
Lysonase Reagent (10 µl/g). The sample was incubated for 15 min and subsequently 
sonicated for 15 cycles at 20% amplitude (1 cycle: 1 sec on with 10 sec off interval). The 
solution was clarified by centrifugation at 13,200 rpm for 10 min. The cleared lysate was 
loaded onto Ni2+-nitrilotriacetate affinity chromatography spin columns. After a washing 
step (20 mM Tris-HCl, 500 mM NaCl, 40 mM imidazole, pH 7.5), the recombinant 
protein was eluted with elution buffer (50 mM Tris-HCl, 300 mM NaCl, 250 mM 
imidazole, pH 7.5). The pellet was suspended in 1 ml solubilisation buffer (50 mM Tris-
HCl, 8 M urea, 300 mM NaCl, 10 mM imidazole, pH 7.5) and incubated for 10 min. 
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With the different collected fractions (flowthrough/wash/eluate) a SDS-PAGE followed 
by Coomassie Blue staining was performed. For continuation, the following expression 
vectors were used: ICD-1 (~ 49 kDa) fused to Trx-6xHis-S-tag (17 kDa) and ICD-2 (~ 82 
kDa) fused to pNAT83 His-tag (46 kDa).  
2.2.3.2 Large Scale Purification  
E. coli Tuner (DE) cells harbouring either ICD-1 fused to Trx-6xHis-S-tag or ICD-2 
fused to MBP-6xHis-S-tag were both precultured in LB medium containing kanamycin. 
After transfer (1/100 dilution) into one litre of Terrific Broth MOPS medium [12 g/l 
Bacto Tryptone (Becton Dickinson), 24 g/l Bacto Yeast Extract (Becton Dickinson), 10 
mM ammonium sulfate, 0.3 mM dipotassium hydrogen phosphate, 0.3 mM potassium 
dihydrogen phosphate, 100 mM MOPS (Sigma), pH 7.0], supplemented with kanamycin, 
growth was permitted for 3-4 hrs at 37ºC, 200 rpm till OD600 of 0.6-0.8 was reached. 
Induction of protein expression was carried out as described for small scale purification 
(section 2.2.3.1). Cells were harvest by centrifugation at 8000 rpm for 30 min at 4ºC. The 
pellet of both constructs (circa 16-20 g/litre) was resuspended in 50 ml binding buffer (50 
mM Tris-HCl, 300 mM NaCl, 10 mM imidazole, pH 7.5) that had been premixed with 
Lysonase Reagent (10 µl/g) and incubated for 10-15 min at RT. The sample was 
sonicated in tubes on ice for 30 cycles at 30% amplitude (1 cycle: 5 sec on with 15 sec 
off interval). The sample was spun down at 17,000 rpm for 30 min at 4ºC. The filtered 
solution (using a 45 µm membrane filter) was subjected to immobilised metal affinity 
chromatography (IMAC). The IMAC column was packed with Ni-NTA agarose (Ni-
NTA His-Bind resins; column volume (CV) was 3 ml). A flow adaptor was attached to 
the column in order to reduce the void volume above the resin. After column 
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equilibration with 10 CV binding buffer the filtered solution was loaded onto the column. 
After a washing step using 5 CV wash buffer (20 mM Tris-HCl, 500 mM NaCl, 40 mM 
imidazole, pH 7.5), recombinant protein was eluted with 6 CV elution buffer (20 Tris-
HCl, 300 mM NaCl, 250 mM imidazole, pH 7.5) using a fraction collector (1 ml 
fraction/min). A rough estimation of the eluted protein fractions was carried out using 1X 
Bradford Reagent. The eluate fractions, displaying the highest protein concentration, 
were pooled and concentrated to about 2.5 ml volume using ultrafiltration spin columns 
at 3000 rpm, 20-30 min, 4ºC. Buffer exchange was carried out using a PD-10 column. 
Protein was eluted in 3.5 ml storage buffer (20 mM Tris-HCl, 300 mM NaCl, 10 % (v/v) 
glycerol, pH 7.5) The protein concentration was determined and a SDS-PAGE followed 
by Coomassie Blue staining was performed. The sample was cleaved with PreScission 
Protease (15 µl/mg) in order to remove the 6xHis-tag. Cleavage was permitted for 24 hrs 
at 4ºC, 60 rpm. The sample was concentrated to 500 µl using a ultrafiltration spin column 
at 3000 rpm, 20-30 min, 4ºC. Afterwards, the sample was loaded onto a prepacked XK 
column designed for preparative gel filtration chromatography separations. Fractions 
were collected (1 ml/fraction) at a flow rate of 0.4 ml/min. To determine the fractions that 
contained cleaved protein, the UNICORN software for control and supervision of 
chromatography was used and a SDS-PAGE followed by Coomassie Blue staining was 
carried out. The fractions containing cleaved protein were pooled and concentrated using 
ultrafiltration spin columns. The concentration of purified ICD-1 and ICD-2 was 
determined. The proteins were divided into aliquots and stored at -80ºC.  
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2.2.4 Enzyme Assays with Purified ICD-1 and ICD-2 
Enzymatic activity of ICD-1 and ICD-2 was measured spectrophotometrically by 
monitoring the time dependent reduction of NADP+ to NADPH at RT at 340 nm 
(absorbance maximum of NADPH). The reaction mixture contained the assay buffer (25 
mM Tris-HCl, 5 mM MgCl2, 100 mM NaCl, pH 7.5), as well as 2 mM final 
concentration of DL-isocitrate and 1 mM final concentration of NADP+. Reactions were 
initiated by adding either ICD-1 or ICD-2, both at a final concentration of 70 nM. 
Activity of the enzymes was measured at four time points (30 min/ 60 min/ 90 min/ 120 
min) and determined by using two standard curves. One standard curve displayed the 
concentration-dependent absorbance of NADPH at 340 nm. The concentration of 
NADPH ranged from 1 mM to 0.5 µM. The other standard curve allowed to determine 
the percentage of NADPH produced. All the obtained data was plotted using the software 
program GraphPad Prism, version 4 for Windows. 
2.2.5 Optimisation of E. coli Isocitrate Dehydrogenase 
2.2.5.1 Modification and Subcloning of E. coli icdopt
The gene icdopt is a modified version of the icd gene from E. coli. Modification consisted 
of base exchange, i.e. replacement of several bases with guanine and cytosine (GC). We 
purchased icdopt, which was inserted in pBSK, from 1st BASE. 
Figure 2.1 shows the E. coli icd gene and the different changes that led to the modified 
gene icdopt. The gene sequence of the parental E. coli icd gene (1251 bp) is displayed in 
black (begins with line 1). The bases in red highlight the GC exchange, thus making the 
E. coli icd gene compatible for BCG. The green labelled T at basepair position 323 was 
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exchanged by site directed mutagenesis (SDM; will be described in section 2.2.5.2) to G. 














12 ..C.GCGGCATCCGCTCGCTGAACGTGGCG..............G.....C..G......  
CTGCGTCCGGTACGTTACTATCAGGGCACTCCAAGCCCGGTTAAACACCCTGAACTGACC 



























TTTGGTGAAGCGATCATCGAAAACATGT  1251 bp 
..C..C..C..C........G.......  1251 bp 
 
 
Figure 2.1 | Gene sequence and modifications of the E. coli icd gene.  
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icdopt was subcloned into pMV262 and further into pMV306, transformed into wt BCG 
and plated on 7H11 agar plates containing kanamycin. 
Substitution of Ser113Ala in icdopt was carried out by using the GeneEditor in vitro Site-
Directed Mutagenesis System Kit from Promega. 
2.2.5.2 Site Directed Mutagenesis of icdopt
Preparation of pBSK as DNA Template. icdopt was inserted into pBSK using BamH1 and 
EcoR1. The vector was transformed (heat-shock) into E.coli JM109 competent cells. 
Alkaline denaturation of purified plasmid DNA was carried out using 0.5 pmol of the 
pBSK vector, 2 µl of 2 M NaOH and 2 mM EDTA in a final volume of 20 µl. The 
reaction mix was incubated at RT for 5 min, then 2 µl of 2M ammonium acetate (pH 4.6) 
and 75 µl of 100% ethanol (4ºC) were added, followed by a additional incubation period 
of 30 min at -70ºC. The DNA was precipitated by centrifugation at 13,000 rpm for 15 
min at 4ºC. The pellet was drained and washed with 200 µl of 70% ethanol (4ºC), 
centrifuged again and then dried under vacuum. The pellet was suspended in 100 µl of 
TE buffer (pH 8.0).  
 
Mutagenesis Reaction. The mutagenesis reaction was based on the hybridization of the 
mutagenic sequence (Figure 2.1) and the selection sequence (provided by the kit) to the 
corresponding sites on pBSK containing icdopt. The reaction mix contained 0.05 pmol of 
the pBSK icdopt, 0.25 pmol of selection oligonucleotides from the top strand 
(phosphorylated; provided by the kit), 1.25 pmol of mutagenic oligonucleotides 
(phosphorylated), annealing 10X Buffer and sterile, deionised water. The final volume of 
the reaction mix was 20 µl. The sequence of the mutagenic oligonucleotides was 5’-
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PhosphateGCGGCATCCGCGCGCTGAACGTGGC-3’ with a substitution of serine to 
alanine at position 113 of the protein. The substitution within icdopt affected the basepair 
at position 323, wherein thymine was substituted with guanine. For the annealing of the 
selection and mutagenic oligonucleotides to pBSK icdopt the reaction mix was heated 
using a heating block to 75ºC for 5 min. Subsequently the heating block was cooled down 
to 37ºC by placing it at RT. For subsequent synthesis and ligation of the mutant strand 5 
µl of sterile, deionised water, 3 µl of synthesis 10X Buffer, 1 µl of T4 DNA Polymerase 
(5-10u) and T4 DNA Ligase (1-3u) were added in this order to the reaction mix, yielding 
a final volume of 30 µl. The reaction was incubated at 37ºC for 90 min.  
 
Transformation. 1.5 µl of the mutagenesis reaction was used to transform BMH 71-18 
mutS competent cells, a mismatch repair minus strain of E.coli. 10 ng of purified plasmid 
DNA was transformed via heat-shock into JM109 competent cells. The mutated cells 
were selected on plates (growth o/n, 37ºC) containing 150 µl of the GeneEditor 
Antibiotic Selection Mix and 2.5 mg of ampicillin per 20 ml of media. Several clones 
were sent for sequencing using the universal primers M13F and M13R. For continuation 
one clone with only the desired point mutation 323T>G in icdopt and no other mutation 
was used. For sequence alignment the NCBI (National Centre for Biotechnology 
Information) BLAST (Basic Local Alignment Search Tool program) was used. 
 
Subcloning and Transformation into BCG. pBSK containing icdopt (Ser113Ala) was 
digested with BamHI and EcoRI and cloned into pMV262, an E. coli–Mycobacterium 
multi-copy shuttle vector, under the transcriptional control of the T7 promoter. Digestion 
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of pMV262 with XbaI and HindIII allowed further subcloning of icdopt (Ser113Ala) into 
pMV306, another E. coli–Mycobacterium single-copy shuttle vector. For growth in LB 
broth or alternatively on 7H11 plates kanamycin was used as an antibiotic selection 
marker. 
Electroporation of the plasmids pMV262 icdopt (Ser113Ala) and pMV306 icdopt 
(Ser113Ala) were carried out using a standard protocol.  
For electroporation 3 µl of the plasmids pMV306 (control) and pMV306 icdopt 
(Ser113Ala)was used. After recovery, cells were plated on 7H11 plates containing 
kanamycin. The plates were incubated at 37ºC for about 3 weeks or until colonies were 
spotted.  
icdopt (Ser113Ala) from pMV262 and pMV306 was amplified by PCR with primers that 
allowed to check for proper insertion of the gene into the plasmid. In addition, 
sequencing of icdopt (Ser113Ala) allowed to check for random point mutations.  
 
2.2.6 Genetic Deletion of BCG icd-1 and icd-2 genes  
The icd-1 and icd-2 genes were disrupted by allelic exchange method using the 
pYUB854 plasmid (Bardarov et al., 2002) displayed in Figure 2.2. The 5'-flank and 3'-
flank of the target loci (Figure 2.3) where amplified by PCR and subcloned into pCR2.1 
TOPO plasmid according to the instruction of the manufacturer. Primers used to amplify 
the 5'-flank and 3'-flank of the target loci are listed in table 2.1. The 5’-flank and 3’-flank 
were cloned on either side of res-hyg-res gene cassette of the pYUB854 plasmid. A sacB-
lacZ  cassette was excised from the pGOAL17 (Parish and Stoker, 2000) and ligated into 
    87  
the PacI site of the pYUB854 plasmid. The final plasmids were UV-irradiated as 
described earlier (Hinds et al., 1999) and electroporated into BCG. The allelic exchange 
(Figure 2.4) was screened and confirmed by PCR in the white transformants resistant to 
hygromycin (Table 2.2). 
 















[5’-ATTCTAGAATAAGCATGTCCTTGATGAGCTT-3’] icd-1 (1230 bp)  
replacement of 





















[5’-ATTCTAGAAAGGCACGCACAATCGGCAGAA-3] icd-2 (2238 bp)  
replacement of 
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Table 2.2 | Confirmation of allelic replacement. The Primers depicted in this table were ents, which indicated if an allelic replacement 
had taken place. 
 
Gene x (i) internal region of gene x (ii) flanking region 5 (ii) flanking region 3’ end of gene x 
icd-1 






forward primer at the 5’ end o
[5’-AGGTACTTGGTGGCCG
reverse primer sequence with
[5’-CACGAGCAGACCTCA
(+/-999 bp) 
reverse primer at the 3’ end of icd1 
[5’- TACCGGCTTTAGTGTCGGCTCT-3’] 
forward primer sequence within hyg 
[5’-ACGGTTGCTAGCACGCGCA-3’] 
icd-2 






forward primer at the 5’ end o
[5’-TGCGGCGGTCTCGAA
reverse primer sequence with
[5’-CACGAGCAGACCTCA
(+/-999 bp) 
reverse primer at the 3’ end of icd2 
[5’-TCGCGGCGGTGATGCCGCCA-3’] 






5' icd-1 insertion (1040 bp)
3' icd-1 insertion (1011 bp)
OriE
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Figure 2.2 | The final plasmid pYUB854. This figure shows the final 
plasmid pYUB854 (approximately 12 kb), with the different inserts: 
Hygromycin (orange), 5’ insertion and 3’ insertion (green), lacZ/sacB 
gene cassette (red). The different restriction enzymes, specific for 
each insert, are shown in red. The origin of replication, oriE, is shown 
in blue. Again, the 5’ and 3’ inserts are representing icd-1, but could 
also stand for icd-2.  














icd1 (1230 bp) metC (1350 bp)











Figure 2.3 | The location of the target gene. The figure above shows the location of the target gene icd-1 (yellow) on the genomic DNA of H37Rv. Also 
depicted are the adjacent genes Rv3338, Rv3337 and metC (yellow and brown); the 3’ and the 5’ inserts (green) and the corresponding primer sequence. Sites 
of insertion are represented by dashed lines. In this figure, the gene of interest is represented by icd-1, but could also be icd-2 since the knockout construction 
was the same. 
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3' icd-1 insertion (1011 bp) 5' icd-1 insertion (1040 bp)
OriE




genomic DNA of 
wt BCG
Rv3337 Hygromycin metC (1350 bp)





icd-1 (1230 bp) metC (1350 bp)
5’ insert (1040 bp)3’ insert (1011 bp)
 
 
Figure 2.4 | Homologues recombination. pYUB854 is linearised. Dashed arrows point from the sites of the 5’ and 3’ inserts on the plasmid to the sites of 
insertion on the BCG wt genome. In the event of allelic replacement, icd-1 is replaced by hyg (orange), oriE and the lacZ/sacB cassette are not inserted into 
the genome. As a consequence of the double crossover, the expression of the active gene is disrupted. The yellow ends of hyg  (figure) indicate that both, 
the 5’ and the 3’ insert contained around 100 bps of icd-1. The homologues recombination was the same for icd-2. 
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2.2.7 Growth Assays 
Growth assays were performed with wt BCG, BCG pMV306 icdBoptB, BCG pMV306 icdBopt B 
(Ser113Ala), BCG ∆icd-1 and BCG ∆icd-2. Cells were grown on glycerol, glucose and 
acetate. In addition, wt BCG and BCG ∆icd-2 were also grown in 7H9 base deprived of 
glutamic acid or alternatively, supplemented with glutamic acid. Assays were carried out 
using T25 flasks. Starting OD B600 Bwas 0.02 in a volume of 12 ml. The day of inoculation 
was defined as day 0. ODB600 Bwas measured about four times between day 1 and day 8. 
The first reading point was variable, starting either at day 1, 2 or 3. The data was plotted 
using the software program GraphPad Prism, version 4 for windows. 
2.2.8 MICB50B Assays with the Compounds Isoniazid and 3-Nitropropionate  
MICB50B assays were carried out with the following BCG strains: wt BCG, BCG ∆icd-1 and 
BCG ∆icd-2. Stocks of the different BCG strains were grown in complete 7H9 medium 
until log phase. The cells were washed, ODB600 B was measured and the cells inoculated into 
medium containing either glycerol, glucose or acetate as sole source of carbon. Starting 
ODB600 B was 0.02. The compounds Isoniazid (INH) and 3-Nitropropionate (3-NP) were 
diluted in 90% DMSO and tested at a concentration range of 5 µM to 0.02 µM in case of 
INH and 1 mM to 1.95 µM in case of 3-NP for all the strains and in all the types of media 
mentioned above. Plates were incubated for 5 days at 37ºC. Growth inhibition was 
measured with an optical density at 600 nm. The data was plotted using the software 
program GraphPad Prism, version 4 for Windows. 
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2.2.9 Enzyme Assays with Crude Cell Extracts 
2.2.9.1 Crude Cell Extraction 
The following BCG strains were grown in glucose and acetate medium until log phase: 
wt BCG, BCG pMV306 icdBoptB, BCG pMV306 icdBopt B (Ser113Ala), BCG ∆icd-1 and BCG 
∆icd-2. Afterwards, the strains were washed twice with 7H9 base and resuspended in 
lysis buffer [25 mM Tris-HCl, 100 mM NaCl, 5 mM MgClB2B, 1 mM DTT, 1 protease 
inhibitor cocktail tablet, EDTA-free (1 tablet/50ml)]. The cultures were bead beated, 
three times for one minute at full speed and at 4ºC. The samples were centrifuged at 
13,200 rpm for 10 min at 4ºC, the supernatants were removed and centrifuged again at 
13,200 rpm for 10 min at 4ºC. The protein concentration was measured and the crude cell 
extracts were stored at 4ºC until use, but not for longer than one week.  
2.2.9.2 Enzyme Assays 
Enzyme assays were carried out with the cell extracts from all BCG strains mentioned 
above. The different cell lysates were diluted in assay buffer (25 mM Tris-HCl pH 7.5, 5 
mM MgCl B2 B, 100 mM NaCl) to a final concentration of 30 µg/ml. Reactions were initiated 
by adding a reaction buffer containing 2 mM final concentration of DL-isocitrate and 1 
mM final concentration of NADPP+P. Enzymatic activity was monitored by measuring the 
production of NADPH spectrophotometrically at 340 nm at the time points 30 min, 60 
min, 90 min and 120 min. As controls, 1 mM final concentration of NADPH and 70 nM 
final concentration of purified ICD-1 and ICD-2 were used. The assays were blanked 
with the lysates containing 1 mM final concentration of NADPP+P. The different values 
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         Results 
3.1 In Quest of the Putative Isocitrate Dehydrogenase Kinase/Phosphatase 
in BCG: Enrichment of ATP-Binding Proteins  
With the objective of identifying the putative Ser/Thr kinase that phosphorylates 
isocitrate dehydrogenase, we tried to extract ATP-binding proteins (ABPs) from crude 
cell extracts using the ProteoEnrich ATP-Binders Kit. The experiment was carried out as 
described in section 2.2.1 of Materials and Methods.  
The different fractions (flowthrough/wash/eluate), collected from the affinity column, 
were used to run an SDS-PAGE. Silver staining of the gel revealed many bands for the 
flowthrough and wash fractions but none for the eluate fraction. No differences were 
found between lysates derived glucose grown bacteria and acetate grown bacteria.  
3.2 The Phosphoproteom of BCG: Purification of Phosphoproteins 
To address the questions if i) ICD-1 and/or ICD-2 were phosphorylated at their amino 
acid residues serine and/or threonine and ii) the phosphorylation status was in 
dependence on the carbon source in the culture medium (glucose or acetate), we made 
use of the Phosphoprotein Purification Kit from Qiagen. The experiment was carried out 
as described in section 2.2.2 of Material and Methods.  
The experiment was carried out with crude cell extracts of either glucose or acetate 
grown wt BCG. Additionally, the experiment was carried out with crude cell extract of 
the human lung adenocarcinoma cells (A549). We used these cells as a positive control 
since the kit was designed for eukaryotic cells. 
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The flowthrough, wash and eluate fractions were collected from the affinity column and 
used for Western transfer. Immunodetection of phosphorylated protein revealed i) many 
bands for the fractions containing the lysate and flowthrough; ii) no bands for the eluate 
fractions; and iii) overall no noticeable differences between the lysates derived from DS 
or AS grown bacteria. In case of the A549 cell line, no bands were detected in the 
flowthrough and wash fractions but by contrast, there were a few bands noticeable in the 
eluate fractions. This indicates that the procedure worked well in the case of eukaryotic 
cells. The reason why we were not able to purify phosphoproteins from BCG cell extracts 
is unclear.  
3.3 Expression and Purification of M. tuberculosis ICD-1 and ICD-2 in E. coli 
3.3.1 Small Scale Purification 
The Gateway system was used for small scale purification of the M. tuberculosis proteins 
ICD-1 and ICD-2. Expression vectors were generated by recombination of a set of entry 
vectors containing one of the two target proteins (ICD-1 or ICD-2) with destination 
vectors carrying 8 different N-terminal fusion tags. All expression vectors shared a 
6xHis-tag, an S-tag, the PreScission site and two restriction sites specific for integration 
of the gene of interest. The recombined vectors where directly transformed into the E. 
coli strain Tuner (DE3). The 8 different types of fusion proteins were expressed under the 
T7 promoter in the transformed cells. The procedure for protein expression is described 
in section 2.2.3.1 of Material and Methods. Ni-NTA spin columns, containing Ni-NTA 
silica, a metal chelate chromatography material with high affinity for 6xHis-tagged 
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proteins, were used to purify the target proteins. SDS-PAGE and Coomassie Blue 
staining allowed evaluation of the best suited fusion tag to express recombinant ICD-1 
and ICD-2 at a high yield and in a predominantly soluble form.  
From the different fractions (i.e. soluble protein/insoluble protein/eluted protein), the 
fraction of insoluble ICD-1 was very big with all fusion tags. Out of the 8 tags, only the 
E. coli N-utilization substance (NusA)-6xHis-S-tag led to a comparatively large amount 
of soluble protein. Performing gel filtration with ICD-1 fused to this particular tag 
resulted in a loss of most protein in the void volume. As a consequence, this construct 
was not considered as the appropriate one. The two fusion proteins containing either the 
E. coli thioredoxin (Trx)-6xHis-S-tag or the Staphylococcus aureus Protein A IgG 
binding double domain (ZZ)-6xHis-S-tag showed a small band on the gel, corresponding 
to the soluble fraction. Since the insoluble fraction for the ZZ-tag protein was much 
bigger than the one for the Trx-tagged protein, the latter one was used for continuation. 
Along with the small fraction of soluble protein obtained for all fusion proteins, the 
fraction with the eluted/purified protein was also found to be small, no matter which 
construct was used. 
The small scale purification of ICD-2 fusion proteins resulted, in comparison to ICD-1, in 
a higher yield of soluble protein concerning several constructs. The biggest portion of 
soluble protein was obtained when ICD-2 was fused to the E. coli nonsecreted maltose 
binding protein (MBP)-tag. In addition, the insoluble fraction was much smaller then the 
soluble one. Insoluble and eluted fractions had about the same band intensity. This 
construct was chosen for continuation.  
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Taken together, the recombinant proteins used for the subsequent large scale purification, 
size exclusion chromatography and enzyme assay were: ICD-1 fused to a Trx-tag and an 
adjacent His- and S-tag; and ICD-2 fused to a MBP-tag and a flanking His- and S-tag. 
The molecular weight (Mw) of Trx was around 17 kDa and the one of MBP 
approximately 46 kDa. The Mw of ICD-1 (~49 kDa) and ICD-2 (~82 kDa) gave rise to 
recombinant proteins having a Mw of around 66 kDa and around 128 kDa, respectively.  
Although the profiles of these two constructs were both not optimal, i.e. soluble and 
purified protein fractions were small, they were the most suitable comparing all the 8 
constructs with each other.  
3.3.2 Large Scale Purification 
Large scale purification was carried out with E. coli Tuner (DE3), transformed with ICD-
1 fused to Trx-6xHis-S-tag (Mw ~66 kDa) and ICD-2 fused to MBP-6xHis-S-tag (Mw 
~128 kDa), in 1 litre culture each. Purification was carried out as described in section 
2.2.3.2 of Materials and Methods. The different fractions (flowthrough/wash/eluate) 
obtained from IMAC were collected and loaded onto a SDS gel. The flowthrough 
fraction appeared mostly as a big smeary band, which allowed us to assume that not all 
recombinant protein had been able to bind to the column. Loading the flowthrough a 
second, or even a third or fourth time onto the column, resulted in a remarkably higher 
yield of eluted protein. During the wash step much recombinant protein was lost as well. 
Performing a gradient step elution allowed us to chose the appropriate concentration of 
imidazole for the wash buffer. Forty mM of imidazole seemed to be suitable for the wash 
process in order to get rid of the majority of impurities and at the same time to prevent a 
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big loss of recombinant protein. The eluted fractions, which showed the highest colour 
conversion when mixed with Bradford reagent were combined and the protein 
concentration was measured using the Protein Quantification Kit from Pierce. This Kit is 
based on the reduction of Cu2+ to Cu1+ by protein in an alkaline medium. Colorimetric 
detection of the cuprous cation (Cu1+) is carried out by using a reagent containing 
bicinchoninic acid (BCA). Using the GraphPad Prism software, we were able to estimate 
the protein concentration, which was ~1.19 mg/ml for ICD-1 and ~2.14 mg/ml for ICD-2. 
From 1 litre culture we extracted about 3 mg of recombinant ICD-1 and 5.4 mg of 
recombinant ICD-2. Figure 3.1 shows the combined eluted fractions, which were 
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Figure 3.1 | Purification and cleavage of 
recombinant ICD-1 and ICD-2. ICD-1 
fused to Trx-6xHis-S-tag and ICD-2 fused to 
MBP-6xHis-S-tag were purified with IMAC 
and subsequently cleaved in order to remove 
their tags. 1, Novex Sharp Protein Standard; 
2, ICD-1 with Trx-6xHis-S-tag (Mw ~66 
kDa) before cleavage process; 3, cleaved 
portion of ICD-1 (~49 kDa) and Trx-6xHis-
S-tag (~17 kDa); 4, ICD-2 with MBP-6xHis-
S-tag (Mw ~128 kDa) before cleavage 
process; 5, cleaved portion of ICD-2 (~82 
kDa) and MBP-6xHis-S-tag (~46 kDa) 
 
Separation of the Trx-6xHis-S-tag and the MBP-6xHis-S-tag from ICD-1 and ICD-2, 
respectively was achieved by a cleavage process performed with PreScission protease 
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(Figure 3.1). It has to be mentioned that the portion of uncleaved protein after the 
cleavage process remained usually quite high, even if an excess of PreScission protease 
was added to the protein sample (Figure 3.2 A an B).  
Gel filtration (also dubbed size exclusion chromatography) allowed for separation of 
ICD-1 and ICD-2 from their specific tags based on differences in hydrodynamic volume. 
The theory behind that is the larger the proteins, the less overall volume to traverse over 
the length of the column and hence, the faster the elution. Proteins of the same size will 
elute together. Due to size separation it is desirable that the target proteins have a 
different size from their tags, in order to ensure their elution in different fractions.  
When using gel filtration, we faced the problem that the highest absorbance was 
measured for the first two fractions, which represent the void volume (~1000 mAU for 
ICD-1 samples, ~500 mAU for ICD-2 samples). Running a gel showed that much of the 
cleaved target protein along with the yet uncleaved protein was found in this two 
fractions (Figure 3.2). Further, enzyme assays revealed that this portion of cleaved 
protein was inactive. The UV peak reflecting the cleaved, active protein was very small, 
i.e. ~200 mAU for ICD-1 and ~400 mAU for ICD-2.  
Considering the efficiency of the purification process, we perceived that there little 
impurities found in the different fractions. Most impurities were found in the void volume 
(first two fractions). The remaining fractions consisted predominantly of uncleaved 
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Figure 3.2 | SDS-PAGE with the different fractions 
from gel filtration. In order to separate ICD-1 and ICD-2 
from their tags and from impurities, gel filtration was 
carried out. A | Gel filtration with ICD-1. 1, Novex Sharp 
Protein Standard; 2,3, void volume containing uncleaved 
ICD-1 (~66 kDa) and cleaved ICD-1 (~49 kDa).The 
cleaved portion turned out to be enzymatic inactive. 4,5,6, 
fractions containing cleaved ICD-1. These portions 
showed enzymatic activity. 6,7, fractions containing the 
Trx-6xHis-S-tag (~17 kDa). 
B | Gel filtration with ICD-2. 1, Novex Sharp Protein 
Standard; 2,3, void volume containing uncleaved ICD-2 
(~128 kDa) and cleaved ICD-2 (~82 kDa). The cleaved 
portions showed no enzymatic activity. 4,5,6, fractions 
containing cleaved and active ICD-2; 7,8,9,10, fractions 









In order to improve the efficiency of the cleavage process and also to obtain a larger 
fraction of cleaved active protein, we changed many parameters of the whole large scale 
protein purification procedure. The modifications included replacing Tris-HCl buffer 
with sodium phosphate buffer; varying the concentration of imidazole in the wash buffer; 
changing amplitude, number of cycles and/or intervals of the cycles during the sonication 
step; introducing a cleavage buffer (50 mM Tris-HCl, 150 mM NaCl, 1 mM DTT, 1 mM 
EDTA, 0.01% Tween-80) and/or altering the duration of the cleavage process with 
PreScission protease. None of these changes resulted in a better profile for the active 
portion of cleaved ICD-1 and ICD-2. However, looking at enzymatic activity, both 
cleaved proteins revealed to be active. 
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3.4 Enzyme Assays with Purified ICD-1 and ICD-2 
All the fractions containing cleaved ICD-1 and ICD-2 (Figure 3.2) were tested for their 
enzymatic activity by measuring the absorbance of NADPH (OD340) at four different time 
points. The experimental procedure is described in section 2.2.4 of Materials and 
Methods. The fractions containing active enzyme where pooled. ICD-1 contained three 
fractions of active enzyme (Figure 3.2 A, column 4,5,6) and ICD-2 contained two 
fractions (Figure 3.2 B, column 4 and 5). The concentration of ICD-1 and ICD-2 was 
determined and found to be 3.76 µM and 8.61 µM, respectively. The pooled samples 
were divided into aliquots and stored at -80ºC. 
 
In order to determine the activity of ICD-1 and ICD-2 we created a standard curve (Table 
3.1), which depicted the concentration-dependent absorbance of NADPH. One mM 
NADPH was found to have an OD340 of about 1.56. Since we used 1 mM NADP+ for the 
assays we could roughly estimate the conversion of NADP+ to NADPH and thus, see 
whether the enzymes were active or not. In addition, a standard curve correlating 
NADPH absorbance with the percentage of NADPH produced was generated (Figure 
3.3).  
 
Enzyme assays were performed with the pooled fractions of ICD-1 and ICD-2. The 
measured NADPH absorbances during the assays were plotted in a graph (Figure 3.4). 
This graph allowed us to estimate the time period in which the NADPH production 
showed a linear increase. Additionally, by using the standard curve (Figure 3.3) we were 
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able to estimate the percentage of NADPH produced from 1 mM NADP+ at four different 
time points (Table 3.2). 
 





































Table 3.1 | Absorbance of NADPH at different concentrations. This table was used to generate a standard 
curve that displayed the concentration-dependent absorbance of NADPH. Measuring the absorbance of NADPH 
during the enzyme assay and comparing the output values with the values from this table allowed to see whether 
the enzyme was active or not. Further, this table also allowed to roughly determine how much NADP+ was 
converted to NADPH.  
 
 
Figure 3.3 | Production of NADPH in percentage. The standard curve was used to link the absorbance of 
NADPH (OD340) with the percentage of NADPH produced during the assay. 100 % NADPH corresponds to 1 
mM NADPH. 
 
We found that 120 min after the initiation of the enzymatic reaction, around 67% 
NADPH had been produced due to the reaction of ICD-1 with isocitrate. In the case of 
CD-2, around 34% of NADPH had been produced within the same timeframe.  
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 % of NADPH 
produced 
 
ICD-1      ICD-2 
30 min 27 14 
60 min 45 24 
90 min 57 28 
120 min 67 36 
Figure 3.4 | Enzymatic activity and the increase in absorbance of NADPH. The figure shows the measured 
absorbance values for NADPH at four time points of the enzymatic assay. There is an increase in absorbance, the 
longer the assay is run. However, the linear increase of NADPH takes place within the first 30 min. Overall, this 
figure shows indirectly that the purified ICD-1 and ICD-2 were enzymatically active.  
 
 
Table 3.2 | Percentage of NADPH production. The use of the standard curve (Figure 3.3) allowed us to 
determine the percentage of NADPH produced at the four different time points of the assay. It was found that the 
longer the duration of the assay, the more NADPH is produced.  
 
Quantification of the NADPH absorbance values, measured during the linear phase of the 
assay, allowed us to determine the enzymatic activity U (Table 3.3). Here, one enzyme 
unit was defined as the amount of NADPH produced in pmol per minute. We found that 
the activity U for ICD-1 was around 900 and for ICD-2 around 463. Calculation of the 
specific activity, i.e. activity U per nmol of enzyme, showed how much NADPH was 
produced per minute per 1 nmol of enzyme. The specific activity for ICD-1 was found to 
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Activity of purified ICD-1 and ICD-2 






ICD-1 27,021 900 128,671 
ICD-2 13,874 463 66,071 
 
 
Table 3.3 | Activity U of ICD-1 and ICD-2. Quantification of the percentage of NADPH produced during 
the linear phase of the assay, allowed us to calculate the activity and the specific activity for ICD-1 and 
ICD-2. 
In order to blank the assay we mixed the assay buffer with 2 mM final concentration of 
DL-isocitrate and 1 mM final concentration of NADP+ but excluded the addition of the 
purified enzyme. The negative control, containing the assay buffer, NADP+ and either 
ICD-1 or ICD-2 but no DL-isocitrate, showed no enzymatic activity. Conversely, the 
positive control, consisting of assay buffer along with DL-isocitrate, NADP+ and 1 mM 
final concentration of NADPH, showed an absorbance of around 1.4. 
3.5 Optimisation of E. coli Isocitrate Dehydrogenase  
3.5.1 Subcloning of E. coli icdopt into BCG and Determination of Phenotype 
The icd gene from E. coli was modified in a way that i) it could exhibit its enzymatic 
function in BCG and ii) it could not get phosphorylated by the putative Ser/Thr kinase of 
BCG. Hence, the enzyme would be rendered in a permanently active state. The gene 
sequence and the modifications are described and illustrated in section 2.2.5.1 of 
Materials and Methods.  
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To accomplish the first condition, multiple adenines and thymidines of the E. coli icd 
gene sequence were replaced by guanines and cytosines (GCs). This was done due to the 
unusual feature of the M. tuberculosis genome. Its base composition shows a high and 
uniform GC content (65.6%) throughout the genome. Base exchange should allow 
expression and enzymatic activity of the modified E. coli icd gene in BCG. Regarding the 
second condition, much is known about the regulation of the branch point and its key 
players ICD, ICL, ICDK/P in E. coli. In contrast, little is known about this regulation in 
M. tuberculosis. Thus, the E. coli icd gene was chosen for inhibition of ICD 
phosphorylation since the mechanism behind is established. Overall, by overexpressing 
the modified icd gene, dubbed icdopt, in BCG, we aimed to dysregulate the branch point 
and hence, proof the concept that the branch point in BCG is regulated in analogy to the 
one in E. coli.  
Sequence alignment, carried out using NCBI BLAST, showed a sequence identity of 82% 
between E. coli icd and icdopt. Importantly, the alignment also showed that no gaps were 
introduced. 
 
The icdopt gene was cloned into the final vector pMV306 and transformed into wt BCG 
before plated on 7H11 agar plates. Around three weeks after plating, we counted about 
the same number of colonies for plates containing either BCG with the empty pMV306 
plasmid (control) or BCG transformed with pMV306 icdopt. However, the colonies 
differed in their size. Colonies of the control strain were much bigger than the ones with 
the modified gene. This fact let us assume that the construct had a toxic effect on the 
cells, thus delaying cell growth. Further, since the number of colonies for both 
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transformants was about the same, we also assumed that icdopt had, at least 
phenotypically, no effect. The absence of phenotypical differences was also observed 
when we carried out growth assays and enzyme assays (for procedure refer to section 
2.2.7 and 2.2.9) with wt BCG (control) and BCG pMV306 icdopt. We found no major 
differences between them, neither in their growth behaviour (data not shown) nor in their 









Glucose grown wt BCG
Acetate grown wt BCG
Acetate grown BCG icdopt














Figure 3.5 | Enzyme assays with BCG icdopt (Ser113Ala). Enzyme assays were carried out with BCG 
pMV306 icdopt and wt BCG (control). No major differences in enzymatic activity were found between the two 
constructs when grown either on glucose or on acetate.  
3.5.2 Site Directed Mutagenesis of icdopt
The introduction of a point mutation into the icdopt  gene could possibly solve both 
problems: i) diminish the activity of the icdopt gene product (ICDopt), and so reduce its 
toxicity to the cell; and ii) prohibit phosphorylation by substituting serine with alanine at 
position 113 of ICDopt. As mentioned earlier, the isocitrate dehydrogenase of E. coli is 
phosphorylated/dephosphorylated by the ICDK/P at its serine 113. The procedure for 
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introducing a point mutation into icdopt is described in section 2.2.5.2 of Materials and 
Methods.  
After subcloning the insert from pBSK into pMV262 and further into pMV306, wt BCG 
was transformed with either pMV306 alone (control) or pMV306 containing icdopt 
(Ser113Ala). As before, the number of colonies found on 7H11 plates were about the 
same for both strains. Additionally, the size of the colonies was about the same too.  
We checked for proper insertion of icdopt (Ser113Ala) into pMV262 by designing 
appropriate primers. Further, from two clones, pMV306 icdopt (Ser113Ala) was digested 
with XbaI and HindIII in order to assure that icdopt had been inserted (Figure 3.6). 
 
2,036-
bp 1     2     3
1000-
 
Figure 3.6 | Confirmation of proper insertion of icdopt (Ser113Ala) into 
pMV306. Two clones of pMV306 harbouring icdopt (Ser113Ala) were 
digested with XbaI and HindIII. 1, 1 Kb DNA ladder; 2, upper band 
displays the digested plasmid (2744 bp) and the insert icdopt (1251 bp) of 
clone 1; 3, clone 2, same appearance as clone 1. 
 
In order to check for the site directed point mutation, and also to make sure that during 
the subcloning process no other mutation was introduced, we sequenced the whole gene 
icdopt (Ser113Ala) after insertion into pMV306. Using NCBI BLAST we found that the 
point mutation at position 323 (gene level) was present and further, no other mutation 
was introduced.  
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3.5.3 Determination of icdopt (Ser113Ala) Phenotype: Growth Assays and Enzyme 
Assays 
The two different assays, growth assay and enzyme assay, are described in section 2.2.7 
and 2.2.9 of Materials and Methods. By carrying out these assays we found no major 
differences between the phenotypes of wt BCG and BCG pMV306 icdopt (Ser113Ala). 
The growth assays (Figure 3.7) showed that BCG harbouring pMV306 icdopt (Ser113Ala) 
grew about the same or somewhat slower than wt BCG, regardless of the type of carbon 
source used. BCG grown on acetate grew generally faster than BCG grown on glucose.  







0.90 wt BCGgrown on glycerol
wt BCG grown on glucose
wt BCG grown on acetate
BCG icdopt (Ser113Ala)
grown on glucose
BCG icdopt (Ser113Ala) grown on
glycerol















Figure 3.7 | Growth assays with BCG icdopt (Ser113Ala). Growth assays were carried out with BCG icdopt 
(Ser113Ala) and wt BCG (control). The figure shows that even after introduction of a point mutation into 
icdopt, which would render the overexpressed enzyme in a permanent active state, no major phenotypic 
differences could be found between the transformed and the control strain.  
The enzyme assays (Figure 3.8) showed that the activity of isocitrate dehydrogenase was 
higher when BCG expressing ICDopt (Ser113Ala) was grown on acetate than on glucose. 
The same was observed with wt BCG that was used as a control. Generally, enzymatic 
activity was slightly lower in the transformed strain than in wt BCG.  
    109  
    110  








wt BCG grown on glucose
BCG icdopt (Ser113Ala)
grown on glucose

















However, the expression of ICDBopt B (Ser113Ala) in BCG did not lead to a dysregulation of 
the branch point since the growth of the recombinant and parental strains were 
comparable on glucose and on acetate. Therefore, we decided to stop further 
investigations at this point.  
3.6 BCG ∆icd-1 and ∆icd-2 Knockout Mutants 
Deletion of the BCG genes icd-1 and icd-2, by replacing the internal gene sequence with 
a hygromycin resistance cassette, was carried out as described in section 2.2.6 of 
Materials and Methods.  
As part of the vector construction, 5’ and 3’ fragments had to be generated and subcloned 
into a pCR2.1-TOPO plasmid vector. Concerning both knockout constructs, multiple 
Figure 3.8 | Enzyme assays with BCG icdBoptB (Ser113Ala). Measuring the enzymatic activity of BCG 
icd BoptB (Ser113Ala) revealed only little differences in comparison to wt BCG. wt BCG showed a higher 
absorbance of NADPH than BCG icd BoptB in both type of media. Overall, a higher absorbance of NADPH 
was measured in acetate medium than in glucose medium.  
TOPO plasmid vectors had to be sent in for sequencing, in order to obtain 5’and 3’ 
inserts without any point mutations.  
All BCG transformants, generated by electroporation, were grown on 7H11 agar plates 
containing hygromycin, sucrose and X-gal, thus, allowing only transformants with a 
double-crossover to survive. Allelic exchange is only possible by homologous 
recombination with double crossover, which would insert the hyg gene but not the 
sacB/lacZ gene cassette into the mycobacterial genome. The counter-selectable marker 
sacB allowed for positive selection of the allelic exchange mutants, because the 
expression of the intact sacB gene would not allow growth on sucrose. Transformants 
that have undergone allelic exchange are hygromycin resistant, sucrose sensitive and 
white in their color since sacB and lacZ are forming a gene cassette. Often, transformants 
are first checked for hygromycin resistance and then screened for growth on sucrose. 
Here, they were subjected to hygromycin and sucrose at the same time, thus, creating a 
double selective pressure. This eventually led to a lower yield of putative double 
knockouts but allowed for a faster procedure of creating mutants since BCG is a slow 
growing bacterium and colonies are only visible on the plate after around 3 weeks.  
In case of an allelic replacement for the icd-1 gene, 10 colonies were observed on a total 
of four plates after around 3 week. In the same timespan, 15 putative knockouts of the 
icd-2 gene were observed on a total of four plates. Some of the colonies were tested for 
allelic replacement by PCR. A knockout event was defined as successful, when the target 
gene was not detectable on an agarose gel but the 5’ and the 3’ flanking regions were 
present. As a control, genomic DNA of H37Rv was amplified by PCR using the same 
primers as for the knockouts. Amplification was visible for the gene of interest but not for 
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the flanking regions. Out of the 10 putative icd-1 knockouts, 7 were subjected to PCR 
and gel electrophoresis and 5 revealed to be real. In case of icd-2, the 9 biggest colonies 
were picked from the plates and 3 were shown to be real knockouts. The knockout clones 
of either gene were pooled and kept as glycerol stock at -80ºC. Icd-1 knockout mutants 
were also checked for the presence of the icd-2 gene in their genome, and vice versa. The 
Figures 3.9 A and 3.9 B show that the genes icd-1 and icd-2 had been substituted with the 





















Figure 3.9 | BCG ∆icd-1 and BCG ∆icd-2 knockout 
mutants. The two agarose gels show the different 
amplified fragments, which indicate that an allelic 
replacement had taken place. The primers used for the 
generation of the different fragments are listed in Talbe 
2.2. 
A | BCG ∆icd-1 knockout mutant. 1, 100 bp DNA 
ladder; 2, deleted icd-1 gene (internal fragment, 316 bp); 
3, flanking region 5’ end (+/-999 bp); 4, flanking region 
3’ end (+/-999 bp); 5, icd-2 internal region (256 bp). 
B | BCG ∆icd-2 knockout mutant. 1, 100 bp DNA 
ladder; 2, deleted icd-2 gene (internal fragment, 256 bp); 
3, flanking region 5’ end (+/-999 bp); 4, flanking region 
3’ end (+/-999 bp); 5, icd-1 internal region (316 bp). 
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3.7 Characterisation of the BCG Knockout Phenotypes 
3.7.1 Growth Assays  
Growth assays were carried out with the strains wt BCG, BCG ∆icd-1 and BCG ∆icd-2 
and are described in section 2.2.7 of Materials and Methods. The objective of using this 
assay was to compare the growth behaviour of the different knockout mutants with wt 
BCG, combined with the effect of the culture medium. Three types of culture media were 
used: BCG culture medium with glycerol as main carbon source; BCG culture medium 
with glucose as sole carbon source; BCG culture medium with acetate as sole source of 
carbon.  
As it is shown in Figure 3.10, the growth behaviour of wt BCG, BCG ∆icd-1 and BCG 
∆icd-2 is about the same, independently from the carbon source in the culture medium. 
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 Figure 3.10 | Growth assays with wt BCG, BCG ∆icd-1 and BCG ∆icd-2 on different carbon 
sources. All the figures show that for each carbon source, the three different strains exhibit the same 
growth behavior. A | The strains were grown on glycerol. B | Bacteria were grown on glucose.  
C | Bacteria were grown on acetate.    114  
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3.7.2 Enzyme Assays  
Enzyme assays were carried out with the cell extracts from wt BCG, BCG ∆icd-1 and 
BCG ∆icd-2. The experimental procedure is described in section 2.2.9.2 of Materials and 
Methods.  
For this type of assay bacteria were grown either on glucose or on acetate. Measuring 
NADPH absorbance we found that both, wt BCG and BCG ∆icd-1 were enzymatically 
active (Figure 3.11). Activity was about the same within one defined culture medium. 
Additionally, enzymatic activity was higher in lysates from bacteria grown on acetate 
than grown on glucose.  
Surprisingly, for the BCG ∆icd-2 mutant no enzymatic activity was detected during the 
assay. This was independently from the carbon source used in the culture medium. 
Indirectly, this result suggests that ICD-1 is not enzymatically active in BCG. The 
























Figure 3.11 | Enzymatic activity of wt BCG and the knockout mutants BCG ∆icd-1 and BCG 
∆icd-2. ICD activity was comparable between the parental and BCG ∆icd-1 strains. The enzymatic 
activity was about the same within one defined medium. Activity was higher in acetate lysates than in 
glucose lysates. The BCG ∆icd-2 strain was completely deprived of ICD activity. 
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aFigure 3.12 | Enzymatic inactivity of BCG ∆icd-2. BCG ∆icd-2 showed no enzymatic activity, 
neither in lysate derived from glucose grown mycobacteria, nor in lysates derived from acetate 
grown mycobacteria. In comparison, BCG ∆icd-1 was found to be enzymatically active in both 
lysates.    116  
 
.7.3 The Carbon Flux is Diverted Through the Glyoxylate Shunt in BCG ∆icd-2  
he assays we have carried out so far led us to observe 1) comparable growth kinetics 
etween all the three BCG strains, on all tested carbon sources and 2) no ICD enzymatic 
ctivity in BCG ∆icd-2, which suggest that ICD-1 does not contribute to the overall 
socitrate activity in BCG. If so, the TCA cycle in the BCG ∆icd-2 mutant would be 
isrupted at the point where isocitrate is converted by ICD to α-ketoglutarate. As a result, 
arbon flux would necessarily have to be diverted through the glyoxylate shunt in order 
o permit the bacteria to grow.  
n order to test the importance of the glyoxylate shunt on the of growth of BCG ∆icd-2, 
e inhibited ICL activity and thus, the operation of the glyoxylate shunt. Inhibition was 
chieved by carrying out MICB50B assays with the compound 3-nitropopionate (3-NP). This 
compound is known for its inhibitory effect on ICL. In addition, MICB50 B assays were 
carried out with the INH compound, whose inhibitory effect does not target the 
metabolism of BCG and thus, could be used as a control.  
3.7.3.1 MICB50B Assays with Isoniazid and 3-Nitropropionate  
MICB50B were carried out with wt BCG, BCG ∆icd-1 and BCG ∆icd-2. The experimental 
procedure is described in section  2.2.8 of Materials and Methods.  
Growing the different strains in the presence of different concentrations of INH resulted 
in an MICB50 Bthat laid between ~ 0.19 and 0.35 µM. No major differences were found 
between the three strains or between the three different carbon sources (Table 3.4). 
 





wt BCG         BCG ∆icd-1    BCG ∆icd-2 
Glycerol medium 0.3323 0.3220 0.2285 
Glucose medium 0.3165 0.3483 0.2216 
Acetate medium 0.2090 0.1973 0.1971 
 Table 3.4 | MICB50 Bin presence of INH. Mycobacteria were exposed to INH and grown on glycerol, 
glucose or acetate medium. The concentration of the compound ranged from 5 µM to 0.02 µM. After 5     117  
 
 
The concentration range for 3-NP used in the assays was from 1 mM to 1.95 µM. 3-NP 
had no inhibitory effect on wt BCG and BCG ∆icd-1 when grown on glycerol or on 
glucose. However, when these two strains where grown on acetate, 3-NP showed an 
inhibitory effect with an MICB50B around 20 µM for wt BCG and around 10 µM for BCG 
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∆icd-1. This result was expected since growth on acetate requires the operation of the 
glyoxylate shunt. 
3-NP showed to have an inhibitory effect on BCG ∆icd-2, no matter if the mutant was 
grown on glycerol, glucose or acetate. MICB50 B for glycerol grown BCG ∆icd-2 was around 
15 µM and dropped further down to around 3 µM when acetate was the sole source of 
carbon (Table 3.5).  
 





wt BCG          BCG ∆icd-1   BCG ∆icd-2 
Glycerol medium >300 >300 11.5 
Glucose medium >300 >300 15.9 
Acetate medium 19.6 10.2 3.5 
 
 
These findings support our model that BCG ∆icd-2 is able to direct its carbon flux into 
the glyoxylate shunt, even when grown on glucose or glycerol. To further confirm our 
results, we tested whether the mutant strain is able to grow on medium lacking glutamic 
acid. This amino acid is produced by a reaction involving α-ketoglutarate, which in turn 
is required for the biosynthesis of amino acids, nucleotides and biological amines. 
 
Table 3.5 | MICB50 Bin presence of 3-NP. Mycobacteria were exposed to 3-NP and grown on glycerol, 
glucose or acetate medium. The concentration of the compound ranged from 1 mM to 1.95 µM. After 5 
days of incubation at 37 ºC, the ODB600 B was recorded and the MICB50 B curve plotted using GraphPad. 
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Figure 3.13 | The 
dependence of the BCG 
∆icd-2 mutant  on 
glutamate. Wt BCG and 
BCG ∆icd-2 were grown A | 
in medium deprived of 
glutamic acid, and B | in 
medium supplemented with 
glutamic acid. wt BCG grew 
well under both conditions, 
whereas growth of BCG 
∆icd-2 was impaired in the 
absence of glutamic acid 
Growth was restored when 
glutamic acid was added to 
the medium. 
3.7.3.2 BCG ∆icd-2 Strains are Auxotrophic for Glutamate 
Growing the BCG ∆icd-2 mutant in 7H9 medium deprived of glutamic acid resulted in a 
restricted growth rate. In contrast, wt BCG showed no growth impairment when cultured 
in this medium. Supplementation of glutamic acid to the medium restored growth of BCG 
∆icd-2. As a consequence, BCG ∆icd-2 seems to be auxotrophic for glutamate. This 
result confirms that BCG ∆icd-2 exhibits no enzymatic activity and hence, cannot 
produce α-ketoglutarate. This means further that the entire carbon flux of this mutant is 
diverted into the glyoxylate shunt.  
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       Discussion 
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The prototrophic feature and metabolic flexibility of M. tuberculosis permit the bacilli to 
oxidise a variety of carbon substrates such as sugars, tricarboxylic acids, fatty acids and 
amino acids (Munoz-Elias and McKinney, 2006). This flexibility is necessary since this 
pathogen survives and persists within macrophages – immune cells, whose task is to kill 
microbes. Thus, the environment that is encountered by the bacilli within a phagosomal 
vacuole of a macrophage is very hostile (Smith, 2003). Nutrient starvation within the 
phagosome, forces the bacilli to shift their primary carbon source to fatty acids that are 
present in the endosomal-lysosomal network of the host cell (Boshoff and Barry, 2005). 
If this is true, then this could be an explanation for the high abundance of genes (>150) 
found in the genome of M. tuberculosis, which encode for enzymes involved in the β-
oxidation of fatty acids (Honer zu Bentrup and Russell, 2001). The hypothesis, which 
proposes that host lipids are the preferred carbon source for M. tuberculosis during 
infection, is supported by the finding that bacteria harvested from infected tissues 
preferentially metabolise fatty acids over carbohydrates (Bloch and Segal, 1956). If host 
lipids are the main carbon source for M. tuberculosis during infection, then a high 
importance has to be given to the glyoxylate shunt; the pathway that allows bacteria to 
grow on fatty acids (Gould et al., 2006). In E. coli it is known that this bypass is 
mobilised when bacteria are grown on acetate or fatty acids. Whether the carbon flux is 
directed to the glyoxylate shunt or continues in the TCA cycle is determined at the branch 
point of these two cycles. There, isocitrate lyase and isocitrate dehydrogenase compete 
for their common substrate, isocitrate (Cozzone, 1998). That this pathway is also 
important in M. tuberculosis was supported by the findings that icl-1 and icl-2, which 
showed to be essential when lipids are the sole source of carbon, are required for growth 
in vivo (McKinney et al., 2000). Given that this shunt is absent in humans, and thus, 
making its enzymes attractive targets for the development of broad-spectrum 
antimicrobials, makes it even more important (Smith et al., 2004).  
 
During this Master project we wanted to gain insight in the regulation of this branch point 
in BCG. Unfortunately, little is known about this anaplerotic bypass in M. tuberculosis, 
in contrast to E. coli, where this pathway is well studied. Since E. coli has only one ICL 
and one ICD, but M. tuberculosis does have two of each, it seems likely that the branch 
point might be differentially regulated. In addition, M. tuberculosis ICD-1 and ICD-2 
have distinct phylogenetic affiliations (Banerjee et al., 2005), raising the possibility that 
they might have different roles in the regulation of the branch point. In the case of M. 
tuberculosis ICDs it has been predicted that the branch point is regulated by 
phosphorylation of ICD-1 (Singh and Ghosh, 2006).  
The putative Ser/Thr kinase 
In order to better understand the regulation of the branch point, we aimed in finding the 
so far unknown, putative M. tuberculosis ICDK/P. From studies in E. coli it is known that 
ICDK/P controls the partitioning of the carbon flux at this particular branch point by 
phosphorylation/dephosphorylation of ICD (Cozzone, 1998). Based on the fact that in E. 
coli the putative ICDK/P is a Ser/Thr kinase (STK) and also a Ser/Thr phosphatase 
(PstP), it may be possible that the putative kinase in M. tuberculosis is also a STK/PstP. 
To date, the family of eukaryotic-like protein kinases and phosphatases found in the 
genome of M. tuberculosis consists of 11 predicted STKs and at least one PstP (Cowley 
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et al., 2004). By using a kit specific for enrichment of ATP-binding proteins, we hoped to 
find the putative kinase in BCG. Unfortunately, we were not able to extract any 
kinase/phosphatase. One possible reason for the failure might be that this kit is designed 
for eukaryotic cells, though we applied it to BCG. Given that there are over 500 putative 
STKs or Tyr protein kinases expressed in humans and over 130 putative protein 
phosphatases (Greenstein et al., 2005), this kit might not have been sensitive enough to 
enrich the 11 STKs in BCG. Furthermore, we faced the problem that BCG cells could not 
be lysed the way it was described in the kit. This is due to the fact that the break down of 
the mycobacterial cell wall requires bead beating. Hence, the difference in obtaining cell 
extracts might have had an issue on the enrichment process. Possibly, one of the many 
parameters such as pH, temperature, reagents etc. might also have had an impact on the 
procedure. 
Expression and Purification of M. tuberculosis ICD-1 and ICD-2 in E. coli 
In association with the aim of identifying the putative ICDK/P, we expressed and purified 
M. tuberculosis ICD-1 and ICD-2 in E. coli. The two enzymes were thought to be in later 
use for the conformation of the expected role of the putative kinase/phosphatase. As 
described in the Results section we were able to purify ICD-1 and ICD-2 and further, 
show that both of them were active. As an incidental remark it is to mention that the 
problems faced during the purification process could possibly be solved by making use of 
the S-tag. This tag was a component of the whole N-terminal fusion tag. An S-tag allows 
another affinity approach in order to purify target proteins. Instead of using metal 
chelation chromatography, purification is achieved by the affinity interaction between S-
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protein, immobilised on agarose beads, and S-tag. Further, extremely pure, intact target 
proteins can be obtained using a combination of N-terminal S-tag and C-terminal His-tag 
sequences (McCormick and Mierendorf, 1994).  
For further investigations, these two purified enzymes could be used for identification of 
the probable ICDK/P. One possibility is to express and purify the 11 STKs from M. 
tuberculosis and to determine, which one can phosphorylate ICD-1 and ICD-2 in vitro. 
Kinase activity could be determined by using radioactive labelled phosphate. Important to 
mention is that the group of Pedro Alzari (Pasteur Institute, France) developed a panel of 
the 11 purified M. tuberculosis STKs that could be used for this purpose.  
Alternatively, by tagging and immobilising the 11 STKs on a resin, they could be used in 
a pull down experiment. Detection of ICD-1 and ICD-2 in the eluate could be carried out 
with ICD-1 and ICD-2 specific antibodies or by using mass spectrometry.  
The Phosphoproteom of BCG: Purification of Phosphoproteins 
One further aspect in the regulation of the branch point involves the finding that in E. coli 
the ICD phosphorylation status is dependent on the carbon source encountered by the 
bacilli (Cozzone, 1998). Assuming that the regulation of the branch point in BCG would 
be in analogy to the one in E. coli, we hoped to identify proteins phosphorylated at their 
serine residue(s) when BCG was grown on acetate, but not when grown on glucose. As 
for the ATP-Binders Kit, we were not able to detect serine phosphorylated proteins by 
Western blotting, after they had been purified using the Phosphoprotein Purification Kit. 
Hence, there was no need to carry out 2D gel electrophoresis for analysing the 
phosphoproteom, derived from BCG grown on different carbon sources. Again, we can 
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only speculate about the failure. Since this kit was designed for eukaryotic cells, it is 
interesting to mention that when using eukaryotic cells (A549) , we were able to detect 
some bands after Western blotting and immunodetection with Ser/Thr antibodies. This 
could mean that there might be differences in the sensitivity of the kit, depending whether 
the purification of phosphoproteins is carried out with prokaryotic or eukaryotic cell 
lysates. Regarding prospective investigations, it shall be mentioned that Macek et al. 
have developed a high-accuracy, high sensitivity method to study the phosphoproteom of 
any species (Macek et al., 2008). They were able to analyse the Ser/Thr/Tyr 
phosphoproteom of E. coli K12 using this particular method. It involves high accuracy 
mass spectrometry in combination with phosphopeptide enrichment. For enrichment, 
strong cation exchange chromatography is used followed by titanium dioxide 
chromatography (Macek et al., 2008). This method could also be applied in order to 
obtain a site-specific, in vivo phosphoproteom of M. tuberculosis. In turn, this could help 
to elucidate various steps in the regulation of the bacterium’s metabolism, possibly also 
the one involved in the regulation of the glyoxylate shunt/TCA cycle branch point.  
Optimised Isocitrate Dehydrogenase  
E. coli’s isocitrate dehydrogenase was modified with the intension to dysregulate the 
branch point. However, BCG harbouring icdopt (Ser113Ala) did not show any phenotypic 
conspicuity, compared to wt BCG, in the growth assays and enzyme assays we have 
performed. This finding was unexpected since the incapability of phosphorylating ICDopt 
(Ser113Ala) should not have allowed the diversion of the carbon flux into the glyoxylate 
bypass. Hence, in presence of acetate, bacterial growth should have been reduced 
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significantly. The explanation behind this assumption is that the higher pool of 
unphosphorylated ICDBopt B should have decreased the probability that ICL binds isocitrate 
due to the low affinity for the substrate. 
However, transformed bacteria grew as fine on acetate as on glucose and further, no 
major difference in growth kinetics was found when compared to wt BCG. Further, since 
the enzymatic activity measured in presence and absence of the modified gene was about 
the same, it seems that somehow overexpression of the construct did not occur or was not 
sufficient.  
The lack of dysregulation suggests a very high robustness of the branch point in 
mycobacteria. This robustness might be due to the presence of two icd genes, or 
alternatively by some fundamental differences in the regulation of the branch point 
between E. coli and mycobacteria. 
Since dysregulation of the branch point could not be achieved using this model, we 
decided to stop further investigations here. Therefore, we constructed two knockout 
mutants, one with a disrupted icd-1, the other with a disrupted icd-2 gene. 
BCG ∆icd-1 and ∆icd-2 Knockout Mutants 
By knocking out the two genes, whose proteins function at the branch point, we hoped to 
find alterations in the regulation of this site. Further, since both mutants display loss-of 
function phenotypes, we also hoped in gaining insight into the nature of ICD-1 and ICD-
2.  
We initially showed that there was no difference in the growth kinetic between the BCG 
parental strain, BCG ∆icd-1 and BCG ∆icd-2 on all carbon sources that were tested. 
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These observations suggested that the deletion of one of the ICD genes was not sufficient 
to compromise the regulation of the branch point.  
However, when the enzyme assays were carried out with the cell free extracts of the 
mutant strains, we found that the BCG ∆icd-2 strain was completely deprived of ICD 
activity. The ICD activity was comparable between the parental and BCG ∆icd-1 strains. 
Taken together, these data suggested that ICD-1 is enzymatically not active in BCG and 
thus, the whole isocitrate dehydrogenase activity derives from ICD-2. In addition, these 
data suggested that the TCA cycle can be interrupted at the level of isocitrate 
dehydrogenase in BCG.  
 
If ICD-1 is effectively enzymatically inactive, then there is need to explain why we did 
not observe differences in the growth kinetics between BCG ∆icd-2 and the other two 
strains. From what is known in E. coli, one should have expected a growth impairment 
for BCG ∆icd-2 in glycerol and glucose, and no growth on acetate (Helling and Adams, 
1970). Thus, an interruption of the TCA cycle at the point, where isocitrate is converted 
to α-ketoglutarate, would have resulted in an impass in terms of energy production and a 
deficiency in amino acid synthesis (because α-ketoglutarate is an essential precursor 
intermediate for amino acid synthesis). Also to mention is that in E. coli the glyoxylate 
shunt is turned off, whenever there is access to a more easily metabolisable carbon source 
(i.e. glycerol or glucose) (Cozzone, 1998). However, a flux of carbon is theoretically 
possible if ICL and malate synthase would be expressed on glucose. To test this 
possibility, we used the specific ICL inhibitor 3-nitropropionate (3-NP) (Sharma et al., 
2000). In M. tuberculosis wt, 3-NP inhibits the growth of the bacteria on acetate (Sharma 
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et al., 2000). As expected, there was no inhibitory effect of 3-NP for BCG ∆icd-1 and for 
the parental strain when grown on glucose or on glycerol. However, the BCG ∆icd-2 
strain was found to be sensitive to 3-NP, not only when grown on acetate, but also when 
grown on glycerol or glucose. Importantly, the minimal inhibitory concentrations of 3-NP 
in BCG ∆icd-2 were similar in all media. From this, we concluded that the entire carbon 
flux in BCG ∆icd-2 is diverted through the glyoxylate shunt, and this independently from 
the carbon source present in the medium. If this is the case, then this might indicate that 
the glyoxylate bypass does not need the operation of the TCA cycle in terms of energy 
and carbon metabolism.  
 
However, our observations do not explain how BCG ∆icd-2 can multiply as efficiently as 
the parental strain. If the entire carbon flux is directed through the glyoxylate shunt due to 
the interruption of the TCA cycle, then the question remains, how the bacteria obtain α-
ketoglutarate and synthesise amino acids. α -ketoglutarate is normally produce in the 
NADP-dependent ICD reaction and is required for ammonium assimilation through the 
glutamine synthetase-glutamate synthase (GS-GOGAT) pathway. It is a key metabolite in 
the linkage of nitrogen and carbon metabolism. (Muro-Pastor et al., 1996).  
This conflict was resolved by demonstrating that BCG ∆icd-2 is unable to multiply in the 
absence of glutamic acid in the culture medium. This auxotrophic phenotype suggests 
that α-ketoglutarate is not produced by BCG ∆icd-2.  
Quantification of α-ketoglutarate in cell lysates from the parental and BCG ∆icd-2 strains 
should lead to no detection of α-ketoglutarate in the mutant strain. In contrast, α-
ketoglutarate should be detectable in the parental strain. 
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To resume, our results suggest that ICD-2 is the only isocitrate dehydrogenase enzyme 
active in BCG. The reason why ICD-1 is not enzymatically active is not clear, but could 
be explained by a lack of expression or by constitutive phosphorylation of the enzyme at 
the active site. That a differential expression of the two isoforms during differential 
stages and conditions of growth cannot be ruled out, even though the enzymes have 
identical enzymatic function, has further been mentioned by Banerjee et al. (Banerjee et 
al., 2005). Experiments with Vibrio sp. showed that ICD-1 and ICD-2 are differentiallyP 
Pregulated in vivo by various growth conditions. ICD-1 was inducedP Pby acetate, while 
ICD-2 remained almost unchanged (Ishii et al., 1993). Thus, differential expression of 
isocitrate dehydrogenases has been found in other bacteria. Examine the transcriptom of 
BCG, in association of the possible differential expression of icd-1 and icd-2 (or the lack 
of expression of ICD-1) in dependence on carbon sources, could help in understanding 
the regulation of the branch point.  
 
Since the measured enzymatic activities of purified ICD-1 and ICD-2 were similar, it 
seems reasonable that in vivo ICD-1 might be constitutively phosphorylated. Singh et al. 
demonstrated, using a modelling system that carbon flux through the glyoxylate shunt 
was only allowed when both, ICD-1 and ICD-2 where more than 70% inactivated (Singh 
and Ghosh, 2006). Having ICD-1 in a constitutively phosphorylated state would lower 
the threshold, which is required to direct the carbon flux through the glyoxylate bypass. 
Though, our finding that in BCG ∆icd-2 the glyoxylate shunt is operating also during 
growth on glycerol and glucose, suggests that the shunt is constitutively expressed. 
    130  
Overall it seems that the glyoxylate shunt produces enough carbon and energy for the 
bacilli to survive.  
 
Looking at BCG ∆icd-1 we found that it grows well in glucose and in presence of 3-NP. 
In other words, it seems that the TCA cycle is functioning and thus, ICD-2 enzymatically 
converts isocitrate to α-ketoglutarate. In presence of acetate and 3-NP growth is impaired 
due to the fact that fatty acids do require an operating glyoxylate shunt to generate some 
biomass. If ICD-1 is constitutively phosphorylated, the question remains how ICD-2 is 
regulated. Possibly, the regulation is based on allosteric effectors. In E. coli it has been 
found that ICD is strongly inhibited by glyoxylate plus oxaloacetate in combination 
(Cozzone, 1998). It would be interesting to investigate if ICD-2 is regulated 
allosterically.  
 
Leaving the speculations about the nature and regulation of ICD-1 and ICD-2 aside and 
coming back to the putative ICDK/P, it seems that out of the 11 predicted STKs, a 
putative candidate could be PknG. In E. coli it was found that ICD showed to be 
dispersed in the cytoplasm (Yasutake et al., 2003). In M. tuberculosis, only two out of the 
11 STKs are predicted to be located in the bacterial cytoplasm. One of them is PknG. The 
pknG gene is located in an operon with glnH, which encodes an extracellular glutamine-
binding protein. In other bacteria, glnH was found to be induced under nitrogen-limiting 
conditions. This is interesting in terms of the findings from the experiments with Vibrio 
sp. (Ishii et al., 1993). Further, it has been hypothesised that the M. tuberculosis PknG 
participates in the metabolism of poly L-glutamate/glutamine (Cowley et al., 2004). 
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Overall, if PknG is the putative ICDK/P, deletion of the pknG gene in BCG ∆icd-2 should 
restore the enzymatic activity of ICD-1 and also render the strain insensitive towards 3-
NP during growth on glucose and glycerol.  
 
 
Taken together, our results suggest that ICD-2 is the only active isocitrate dehydrogenase 
enzyme in BCG. Further, the inactivity of ICD-1 requires a constantly operating 
glyoxylate shunt in order to permit growth of the BCG ∆icd-2 mutant. Thus, we predict 
that ICD-1 and ICD-2 differ in their function and possibly in the way they are regulated 
by the putative kinase/phosphatase.  
 
 
Forthcoming investigations involving ICD-1 and ICD-2 could entail explanations why 
there are two isocitrate dehydrogenases in M. tuberculosis. Revelation of possible 
functional differences between the two isocitrate dehydrogenases could lead to the 
understanding of the branch point regulation. It could also allow to define the role of the 
putative ICDK/P in M. tuberculosis. This in turn might be supportive in finding the 
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